TY  - CONF
AU  - Perić, Jelena
AU  - Pavlović, Dunja
AU  - Dragičević, Sandra
AU  - Miladinov, Marko
AU  - Djikić-Rom, Aleksandra
AU  - Bjelanović, Jasna
AU  - Kovač, Jelena
AU  - Despotović, Jovana
AU  - Babić, Tamara
AU  - Rosic, Jovana
AU  - Dimitrijević, Ivan
AU  - Marković, Velimir
AU  - Barisic, Goran
AU  - Nikolić, Aleksandra
PY  - 2023
UR  - https://2023.eshg.org/
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2061
AB  - The cornerstone in the treatment of locally advanced rectal cancer (LARC) is neoadjuvant
chemoradiotherapy (nCRT) followed by total mesorectal excision. Reliable predictors of
response to nCRT in LARC remain an unmet need in colorectal cancer research. This study
used high throughput DNA analysis to investigate genetic differences between highly
responsive tumors and tumors resistant to nCRT.
C3  - ESHG 2023
T1  - Genetic determinants of response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer identified by whole exome sequencing
UR  - https://hdl.handle.net/21.15107/rcub_imagine_2061
ER  - 

@conference{
author = "Perić, Jelena and Pavlović, Dunja and Dragičević, Sandra and Miladinov, Marko and Djikić-Rom, Aleksandra and Bjelanović, Jasna and Kovač, Jelena and Despotović, Jovana and Babić, Tamara and Rosic, Jovana and Dimitrijević, Ivan and Marković, Velimir and Barisic, Goran and Nikolić, Aleksandra",
year = "2023",
abstract = "The cornerstone in the treatment of locally advanced rectal cancer (LARC) is neoadjuvant
chemoradiotherapy (nCRT) followed by total mesorectal excision. Reliable predictors of
response to nCRT in LARC remain an unmet need in colorectal cancer research. This study
used high throughput DNA analysis to investigate genetic differences between highly
responsive tumors and tumors resistant to nCRT.",
journal = "ESHG 2023",
title = "Genetic determinants of response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer identified by whole exome sequencing",
url = "https://hdl.handle.net/21.15107/rcub_imagine_2061"
}

Perić, J., Pavlović, D., Dragičević, S., Miladinov, M., Djikić-Rom, A., Bjelanović, J., Kovač, J., Despotović, J., Babić, T., Rosic, J., Dimitrijević, I., Marković, V., Barisic, G.,& Nikolić, A.. (2023). Genetic determinants of response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer identified by whole exome sequencing. in ESHG 2023.
https://hdl.handle.net/21.15107/rcub_imagine_2061

Perić J, Pavlović D, Dragičević S, Miladinov M, Djikić-Rom A, Bjelanović J, Kovač J, Despotović J, Babić T, Rosic J, Dimitrijević I, Marković V, Barisic G, Nikolić A. Genetic determinants of response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer identified by whole exome sequencing. in ESHG 2023. 2023;.
https://hdl.handle.net/21.15107/rcub_imagine_2061 .

Perić, Jelena, Pavlović, Dunja, Dragičević, Sandra, Miladinov, Marko, Djikić-Rom, Aleksandra, Bjelanović, Jasna, Kovač, Jelena, Despotović, Jovana, Babić, Tamara, Rosic, Jovana, Dimitrijević, Ivan, Marković, Velimir, Barisic, Goran, Nikolić, Aleksandra, "Genetic determinants of response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer identified by whole exome sequencing" in ESHG 2023 (2023),
https://hdl.handle.net/21.15107/rcub_imagine_2061 .

TY  - JOUR
AU  - Jovanović, Emilija
AU  - Babić, Tamara
AU  - Dragičević, Sandra
AU  - Kmezic, Stefan
AU  - Nikolić, Aleksandra
PY  - 2023
UR  - https://onlinelibrary.wiley.com/doi/abs/10.1002/cbf.3890
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2223
AB  - The role of tetraspanin CD81 in malignant transformation is best studied in colorectal cancer, and it appears that other transcripts beside the fully coding mRNA may also be dysregulated in malignant cells. Recent data from a comprehensive pan-cancer transcriptome analysis demonstrated differential activity of two alternative CD81 gene promoters in malignant versus nonmalignant gut mucosa. The promoter active in gut mucosa gives rise to transcripts CD81-203 and CD81-213, while the promoter active in colon and rectal cancer gives rise to transcripts CD81-205 and CD81-215. Our study aimed to explore the biomarker potential of the transcripts from the alternative CD81 gene promoters in colon cancer, as well as to investigate their structure and potential function using in silico tools. The analysis of the transcripts' expression in several colon cell lines cultivated in 2D and 3D and a set of colon cancer and healthy gut mucosa samples by qPCR and RNA sequencing suggested their low expression and stromal origin. Expression patterns in tumor and nontumor tissue along with in silico data suppose that the transcript CD81-215 may be a noncoding RNA of stromal origin with possible involvement in signaling related to malignant transformation.
T2  - Cell Biochemistry and Function
T1  - Transcript CD81-215 may be a long noncoding RNA of stromal origin with tumor-promoting role in colon cancer
IS  - n/a
VL  - n/a
DO  - 10.1002/cbf.3890
ER  - 

@article{
author = "Jovanović, Emilija and Babić, Tamara and Dragičević, Sandra and Kmezic, Stefan and Nikolić, Aleksandra",
year = "2023",
abstract = "The role of tetraspanin CD81 in malignant transformation is best studied in colorectal cancer, and it appears that other transcripts beside the fully coding mRNA may also be dysregulated in malignant cells. Recent data from a comprehensive pan-cancer transcriptome analysis demonstrated differential activity of two alternative CD81 gene promoters in malignant versus nonmalignant gut mucosa. The promoter active in gut mucosa gives rise to transcripts CD81-203 and CD81-213, while the promoter active in colon and rectal cancer gives rise to transcripts CD81-205 and CD81-215. Our study aimed to explore the biomarker potential of the transcripts from the alternative CD81 gene promoters in colon cancer, as well as to investigate their structure and potential function using in silico tools. The analysis of the transcripts' expression in several colon cell lines cultivated in 2D and 3D and a set of colon cancer and healthy gut mucosa samples by qPCR and RNA sequencing suggested their low expression and stromal origin. Expression patterns in tumor and nontumor tissue along with in silico data suppose that the transcript CD81-215 may be a noncoding RNA of stromal origin with possible involvement in signaling related to malignant transformation.",
journal = "Cell Biochemistry and Function",
title = "Transcript CD81-215 may be a long noncoding RNA of stromal origin with tumor-promoting role in colon cancer",
number = "n/a",
volume = "n/a",
doi = "10.1002/cbf.3890"
}

Jovanović, E., Babić, T., Dragičević, S., Kmezic, S.,& Nikolić, A.. (2023). Transcript CD81-215 may be a long noncoding RNA of stromal origin with tumor-promoting role in colon cancer. in Cell Biochemistry and Function, n/a(n/a).
https://doi.org/10.1002/cbf.3890

Jovanović E, Babić T, Dragičević S, Kmezic S, Nikolić A. Transcript CD81-215 may be a long noncoding RNA of stromal origin with tumor-promoting role in colon cancer. in Cell Biochemistry and Function. 2023;n/a(n/a).
doi:10.1002/cbf.3890 .

Jovanović, Emilija, Babić, Tamara, Dragičević, Sandra, Kmezic, Stefan, Nikolić, Aleksandra, "Transcript CD81-215 may be a long noncoding RNA of stromal origin with tumor-promoting role in colon cancer" in Cell Biochemistry and Function, n/a, no. n/a (2023),
https://doi.org/10.1002/cbf.3890 . .

TY  - CONF
AU  - Erić, Katarina
AU  - Miladinov, Marko
AU  - Dragičević, Sandra
AU  - Rosić, Jovana
AU  - Barišić, Goran
AU  - Marković, Velimir
AU  - Zeljić, Katarina
PY  - 2023
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2099
AB  - Patients with locally advanced rectal cancer are mainly treated with chemoradiotherapy (CRT) before
surgery. Less than 20% of patients respond completely to neoadjuvant CRT. To avoid unnecessary treatment, biomarkers
are being sought to identi fy pati ents with rectal cancer who do not respond to therapy. The HOX Transcript Anti sense
Intergenic RNA (HOTAIR) is a long non-coding trans-acti ng RNA molecule that is frequently deregulated in cancers of
the digestive tract and plays a role in chemoresistance. The aim of this study was to investigate HOTAIR as a potential
biomarker for predicting treatment response in patients with rectal cancer.
PB  - Belgrade :  Serbian Association on for Cancer Research
C3  - 6th Congress of the Serbian Association for Cancer Research (SDIR)
T1  - Expression of long non-coding RNA HOTAIR in rectal cancer as a potential predictor of response to chemoradiotherapy
EP  - 82
IS  - 1
SP  - 82
UR  - https://hdl.handle.net/21.15107/rcub_imagine_2099
ER  - 

@conference{
author = "Erić, Katarina and Miladinov, Marko and Dragičević, Sandra and Rosić, Jovana and Barišić, Goran and Marković, Velimir and Zeljić, Katarina",
year = "2023",
abstract = "Patients with locally advanced rectal cancer are mainly treated with chemoradiotherapy (CRT) before
surgery. Less than 20% of patients respond completely to neoadjuvant CRT. To avoid unnecessary treatment, biomarkers
are being sought to identi fy pati ents with rectal cancer who do not respond to therapy. The HOX Transcript Anti sense
Intergenic RNA (HOTAIR) is a long non-coding trans-acti ng RNA molecule that is frequently deregulated in cancers of
the digestive tract and plays a role in chemoresistance. The aim of this study was to investigate HOTAIR as a potential
biomarker for predicting treatment response in patients with rectal cancer.",
publisher = "Belgrade :  Serbian Association on for Cancer Research",
journal = "6th Congress of the Serbian Association for Cancer Research (SDIR)",
title = "Expression of long non-coding RNA HOTAIR in rectal cancer as a potential predictor of response to chemoradiotherapy",
pages = "82-82",
number = "1",
url = "https://hdl.handle.net/21.15107/rcub_imagine_2099"
}

Erić, K., Miladinov, M., Dragičević, S., Rosić, J., Barišić, G., Marković, V.,& Zeljić, K.. (2023). Expression of long non-coding RNA HOTAIR in rectal cancer as a potential predictor of response to chemoradiotherapy. in 6th Congress of the Serbian Association for Cancer Research (SDIR)
Belgrade :  Serbian Association on for Cancer Research.(1), 82-82.
https://hdl.handle.net/21.15107/rcub_imagine_2099

Erić K, Miladinov M, Dragičević S, Rosić J, Barišić G, Marković V, Zeljić K. Expression of long non-coding RNA HOTAIR in rectal cancer as a potential predictor of response to chemoradiotherapy. in 6th Congress of the Serbian Association for Cancer Research (SDIR). 2023;(1):82-82.
https://hdl.handle.net/21.15107/rcub_imagine_2099 .

Erić, Katarina, Miladinov, Marko, Dragičević, Sandra, Rosić, Jovana, Barišić, Goran, Marković, Velimir, Zeljić, Katarina, "Expression of long non-coding RNA HOTAIR in rectal cancer as a potential predictor of response to chemoradiotherapy" in 6th Congress of the Serbian Association for Cancer Research (SDIR), no. 1 (2023):82-82,
https://hdl.handle.net/21.15107/rcub_imagine_2099 .

TY  - CONF
AU  - Dragičević, Sandra
AU  - Babić, Tamara
AU  - Miladinov, Marko
AU  - Kmezić, Stefan
AU  - Nikolić, Aleksandra
PY  - 2023
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2098
AB  - The activity profi le of alternative promoters may be an indicator of tumor characteristics. Alternative promoters of CD81 gene were shown to be differentially active in colon and rectal cancer tissue. The promoter active in colon and rectal cancer gives rise to transcripts CD81-205 and CD81-215, while the promoter active in normal gut mucosa gives rise to transcripts CD81-203 and CD81-213. This study aimed to analyze the relative abundance of the CD81 gene transcripts in colorectal cancer.
PB  - Belgrade : Serbian Association on for Cancer Research
C3  - 6th Congress of the Serbian AssociaƟ on for Cancer Research (SDIR)
T1  - Expression profile of CD81 gene transcripts in colorectal cancer
EP  - 81
IS  - 1
SP  - 81
UR  - https://hdl.handle.net/21.15107/rcub_imagine_2098
ER  - 

@conference{
author = "Dragičević, Sandra and Babić, Tamara and Miladinov, Marko and Kmezić, Stefan and Nikolić, Aleksandra",
year = "2023",
abstract = "The activity profi le of alternative promoters may be an indicator of tumor characteristics. Alternative promoters of CD81 gene were shown to be differentially active in colon and rectal cancer tissue. The promoter active in colon and rectal cancer gives rise to transcripts CD81-205 and CD81-215, while the promoter active in normal gut mucosa gives rise to transcripts CD81-203 and CD81-213. This study aimed to analyze the relative abundance of the CD81 gene transcripts in colorectal cancer.",
publisher = "Belgrade : Serbian Association on for Cancer Research",
journal = "6th Congress of the Serbian AssociaƟ on for Cancer Research (SDIR)",
title = "Expression profile of CD81 gene transcripts in colorectal cancer",
pages = "81-81",
number = "1",
url = "https://hdl.handle.net/21.15107/rcub_imagine_2098"
}

Dragičević, S., Babić, T., Miladinov, M., Kmezić, S.,& Nikolić, A.. (2023). Expression profile of CD81 gene transcripts in colorectal cancer. in 6th Congress of the Serbian AssociaƟ on for Cancer Research (SDIR)
Belgrade : Serbian Association on for Cancer Research.(1), 81-81.
https://hdl.handle.net/21.15107/rcub_imagine_2098

Dragičević S, Babić T, Miladinov M, Kmezić S, Nikolić A. Expression profile of CD81 gene transcripts in colorectal cancer. in 6th Congress of the Serbian AssociaƟ on for Cancer Research (SDIR). 2023;(1):81-81.
https://hdl.handle.net/21.15107/rcub_imagine_2098 .

Dragičević, Sandra, Babić, Tamara, Miladinov, Marko, Kmezić, Stefan, Nikolić, Aleksandra, "Expression profile of CD81 gene transcripts in colorectal cancer" in 6th Congress of the Serbian AssociaƟ on for Cancer Research (SDIR), no. 1 (2023):81-81,
https://hdl.handle.net/21.15107/rcub_imagine_2098 .

TY  - CONF
AU  - Ignjatović, Sofija
AU  - Pavlović, Dunja
AU  - Babić, Tamara
AU  - Dragičević, Sandra
AU  - Nikolić, Aleksandra
PY  - 2023
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2136
AB  - Introduction: A recent comprehensive pan-cancer transcriptome analysis revealed differential activity
of two alternative promoters of the gene PHF19 in malignant and non-malignant gut mucosa. Transcription from the promoter which is up-regulated in colorectal cancer results in the synthesis of transcript PHF19-207. This finding indicates that transcript PHF19-207 could potentially be used as a
biomarker for this disease. Our study aimed to assess the expression profile of the PHF19 gene in colon
cancer.
Methods: Immortalized colonic epithelial cell line isolated from healthy tissue (HCEC-1CT) as well as a
set of colon cancer cell lines (DLD1, SW620, HCT116) were used for transcriptional profiling of PHF19 in
cells cultivated in 3D. The transcriptional profile was obtained using RNA sequencing and the function
of transcript PHF19-207 was evaluated using in silico tools.
Results: Our analysis confirmed the up-regulation of transcript PHF19-207 in all malignant cell cultures
in comparison to the healthy cell line HCEC-1CT. The expression of transcript PHF19-207 was more notable in cell lines that originated from colon cancer in later stages. Coding Potential Calculator tool classifies this transcript as non-coding, with a probability of 0.2. Annolnc tool shows the up-regulation of
thistranscript in colorectal cancer cell lines and its down-regulation in healthy samples. Also, thistool predicts that transcript PHF19-207 localizes in the nucleus.
Conclusion: We conclude that transcript PHF19-207 could serve as a biomarker for colorectal cancer.
Also, we hypothesize that thistranscript is a lncRNA with a role in gene expression regulation and could
be linked to oncogenesis.
PB  - Institute of Molecular Genetics and Genetic Engineering (IMGGE), University of Belgrade
C3  - CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia
T1  - Transcriptional profiling of PHF19 gene in colon cancer cell lines cultivated in 3D
EP  - 178
SP  - 178
UR  - https://hdl.handle.net/21.15107/rcub_imagine_2136
ER  - 

@conference{
author = "Ignjatović, Sofija and Pavlović, Dunja and Babić, Tamara and Dragičević, Sandra and Nikolić, Aleksandra",
year = "2023",
abstract = "Introduction: A recent comprehensive pan-cancer transcriptome analysis revealed differential activity
of two alternative promoters of the gene PHF19 in malignant and non-malignant gut mucosa. Transcription from the promoter which is up-regulated in colorectal cancer results in the synthesis of transcript PHF19-207. This finding indicates that transcript PHF19-207 could potentially be used as a
biomarker for this disease. Our study aimed to assess the expression profile of the PHF19 gene in colon
cancer.
Methods: Immortalized colonic epithelial cell line isolated from healthy tissue (HCEC-1CT) as well as a
set of colon cancer cell lines (DLD1, SW620, HCT116) were used for transcriptional profiling of PHF19 in
cells cultivated in 3D. The transcriptional profile was obtained using RNA sequencing and the function
of transcript PHF19-207 was evaluated using in silico tools.
Results: Our analysis confirmed the up-regulation of transcript PHF19-207 in all malignant cell cultures
in comparison to the healthy cell line HCEC-1CT. The expression of transcript PHF19-207 was more notable in cell lines that originated from colon cancer in later stages. Coding Potential Calculator tool classifies this transcript as non-coding, with a probability of 0.2. Annolnc tool shows the up-regulation of
thistranscript in colorectal cancer cell lines and its down-regulation in healthy samples. Also, thistool predicts that transcript PHF19-207 localizes in the nucleus.
Conclusion: We conclude that transcript PHF19-207 could serve as a biomarker for colorectal cancer.
Also, we hypothesize that thistranscript is a lncRNA with a role in gene expression regulation and could
be linked to oncogenesis.",
publisher = "Institute of Molecular Genetics and Genetic Engineering (IMGGE), University of Belgrade",
journal = "CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia",
title = "Transcriptional profiling of PHF19 gene in colon cancer cell lines cultivated in 3D",
pages = "178-178",
url = "https://hdl.handle.net/21.15107/rcub_imagine_2136"
}

Ignjatović, S., Pavlović, D., Babić, T., Dragičević, S.,& Nikolić, A.. (2023). Transcriptional profiling of PHF19 gene in colon cancer cell lines cultivated in 3D. in CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia
Institute of Molecular Genetics and Genetic Engineering (IMGGE), University of Belgrade., 178-178.
https://hdl.handle.net/21.15107/rcub_imagine_2136

Ignjatović S, Pavlović D, Babić T, Dragičević S, Nikolić A. Transcriptional profiling of PHF19 gene in colon cancer cell lines cultivated in 3D. in CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia. 2023;:178-178.
https://hdl.handle.net/21.15107/rcub_imagine_2136 .

Ignjatović, Sofija, Pavlović, Dunja, Babić, Tamara, Dragičević, Sandra, Nikolić, Aleksandra, "Transcriptional profiling of PHF19 gene in colon cancer cell lines cultivated in 3D" in CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia (2023):178-178,
https://hdl.handle.net/21.15107/rcub_imagine_2136 .

TY  - CONF
AU  - Erić, K.
AU  - Rosić, Jovana
AU  - Miladinov, Marko
AU  - Dragičević, Sandra
AU  - Barišić, Goran
AU  - Marković, V.
AU  - Zeljić, Katarina
PY  - 2023
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2081
AB  - Background & objectives: The NEAT1 (Nuclear Paraspeckle Assembly Transcript 1) gene encodes a long non-coding RNA that is deregulated in carcinomas of the gastrointestinal tract. Diagnostic and predictive potential of NEAT1 was investigated in patients with locally
advanced rectal cancer.
Methods: The study group consisted of 19 patients with rectal cancer
treated with neoadjuvant chemoradiotherapy (nCRT). RNA was isolated with TRIzol reagent from samples of rectal cancer and noncancerous tissue before and after nCRT. The relative expression level of
NEAT1 normalised to GAPDH was determined by qRT-PCR method.
Results: Expression of NEAT1 did not difer between rectal cancer and
noncancerous tissue before nCRT (p=0.953) and cancer and noncancerous tissue after nCRT (p=0.210). There was no diference in NEAT1
expression between tumour tissue before and after nCRT (p=0.079).
NEAT1 was signifcantly higher in noncancerous tissue before than
after nCRT (p=0.005). Therapy responders (TRG1, TRG2) and nonresponders (TRG3, TRG4) did not difer in NEAT1 levels in tumour
tissue before (p=0.790) and after nCRT (p=0.352). NEAT1 expression
in rectal cancer tissue before nCRT cannot be used as a biomarker to
distinguish responders from non-responders (AUC=0.559, 95%CI=0-
1, p=0.790). Demographic and clinicopathological characteristics were
not associated with NEAT1 expression in rectal cancer tissue.
Conclusion: The obtained results suggest that the long noncoding
RNA NEAT1 cannot be considered as a biomarker with diagnostic
potential or for predicting response to nCRT in patients with rectal
cancer. Validation of the current results in a larger group of patients
with locally advanced rectal cancer is warranted.
PB  - Springer
C3  - Virchows Archiv, 35th European Congress of Pathology  Pathology – a bridge between Science and Medicine, 9 – 13 September
T1  - Long non-coding RNA NEAT1 cannot be used as a diagnostic and prognostic biomarker in patients with locally advanced rectal cancer
EP  - S307
IS  - Supplement 1
SP  - S307
SP  - E-PS-15-011
VL  - 483
UR  - https://hdl.handle.net/21.15107/rcub_imagine_2081
ER  - 

@conference{
author = "Erić, K. and Rosić, Jovana and Miladinov, Marko and Dragičević, Sandra and Barišić, Goran and Marković, V. and Zeljić, Katarina",
year = "2023",
abstract = "Background & objectives: The NEAT1 (Nuclear Paraspeckle Assembly Transcript 1) gene encodes a long non-coding RNA that is deregulated in carcinomas of the gastrointestinal tract. Diagnostic and predictive potential of NEAT1 was investigated in patients with locally
advanced rectal cancer.
Methods: The study group consisted of 19 patients with rectal cancer
treated with neoadjuvant chemoradiotherapy (nCRT). RNA was isolated with TRIzol reagent from samples of rectal cancer and noncancerous tissue before and after nCRT. The relative expression level of
NEAT1 normalised to GAPDH was determined by qRT-PCR method.
Results: Expression of NEAT1 did not difer between rectal cancer and
noncancerous tissue before nCRT (p=0.953) and cancer and noncancerous tissue after nCRT (p=0.210). There was no diference in NEAT1
expression between tumour tissue before and after nCRT (p=0.079).
NEAT1 was signifcantly higher in noncancerous tissue before than
after nCRT (p=0.005). Therapy responders (TRG1, TRG2) and nonresponders (TRG3, TRG4) did not difer in NEAT1 levels in tumour
tissue before (p=0.790) and after nCRT (p=0.352). NEAT1 expression
in rectal cancer tissue before nCRT cannot be used as a biomarker to
distinguish responders from non-responders (AUC=0.559, 95%CI=0-
1, p=0.790). Demographic and clinicopathological characteristics were
not associated with NEAT1 expression in rectal cancer tissue.
Conclusion: The obtained results suggest that the long noncoding
RNA NEAT1 cannot be considered as a biomarker with diagnostic
potential or for predicting response to nCRT in patients with rectal
cancer. Validation of the current results in a larger group of patients
with locally advanced rectal cancer is warranted.",
publisher = "Springer",
journal = "Virchows Archiv, 35th European Congress of Pathology  Pathology – a bridge between Science and Medicine, 9 – 13 September",
title = "Long non-coding RNA NEAT1 cannot be used as a diagnostic and prognostic biomarker in patients with locally advanced rectal cancer",
pages = "S307-S307-E-PS-15-011",
number = "Supplement 1",
volume = "483",
url = "https://hdl.handle.net/21.15107/rcub_imagine_2081"
}

Erić, K., Rosić, J., Miladinov, M., Dragičević, S., Barišić, G., Marković, V.,& Zeljić, K.. (2023). Long non-coding RNA NEAT1 cannot be used as a diagnostic and prognostic biomarker in patients with locally advanced rectal cancer. in Virchows Archiv, 35th European Congress of Pathology  Pathology – a bridge between Science and Medicine, 9 – 13 September
Springer., 483(Supplement 1), S307-S307.
https://hdl.handle.net/21.15107/rcub_imagine_2081

Erić K, Rosić J, Miladinov M, Dragičević S, Barišić G, Marković V, Zeljić K. Long non-coding RNA NEAT1 cannot be used as a diagnostic and prognostic biomarker in patients with locally advanced rectal cancer. in Virchows Archiv, 35th European Congress of Pathology  Pathology – a bridge between Science and Medicine, 9 – 13 September. 2023;483(Supplement 1):S307-S307.
https://hdl.handle.net/21.15107/rcub_imagine_2081 .

Erić, K., Rosić, Jovana, Miladinov, Marko, Dragičević, Sandra, Barišić, Goran, Marković, V., Zeljić, Katarina, "Long non-coding RNA NEAT1 cannot be used as a diagnostic and prognostic biomarker in patients with locally advanced rectal cancer" in Virchows Archiv, 35th European Congress of Pathology  Pathology – a bridge between Science and Medicine, 9 – 13 September, 483, no. Supplement 1 (2023):S307-S307,
https://hdl.handle.net/21.15107/rcub_imagine_2081 .

TY  - CONF
AU  - Ignjatović, Sofija
AU  - Pavlović, Dunja
AU  - Babić, Tamara
AU  - Dragičević, Sandra
AU  - Nikolić, Aleksandra
PY  - 2023
UR  - https://febs.onlinelibrary.wiley.com/doi/10.1002/1878-0261.13471
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1971
AB  - Introduction: Recent data from a comprehensive pan-cancer
transcriptome analysis demonstrated differential activity of
two alternative PHF19 gene promoters in malignant vs.
non-malignant gut mucosa. The promoter found to be upregulated
in colon and rectal cancer gives rise to the
transcript PHF19-207. This finding has pointed to the
biomarker potential and possible tumor-promoting role of
this transcript. Our study aimed to evaluate the expression
of PHF19-207 in colon cancer, as well as to investigate its
potential function using in silico tools.
PB  - Wiley
C3  - Molecular oncology
T1  - Biomarker potential of the transcript PHF19-207 in colon cancer
IS  - Supplement 1
SP  - 70
SP  - 70
VL  - 17
DO  - doi.org/10.1002/1878-0261.13471
ER  - 

@conference{
author = "Ignjatović, Sofija and Pavlović, Dunja and Babić, Tamara and Dragičević, Sandra and Nikolić, Aleksandra",
year = "2023",
abstract = "Introduction: Recent data from a comprehensive pan-cancer
transcriptome analysis demonstrated differential activity of
two alternative PHF19 gene promoters in malignant vs.
non-malignant gut mucosa. The promoter found to be upregulated
in colon and rectal cancer gives rise to the
transcript PHF19-207. This finding has pointed to the
biomarker potential and possible tumor-promoting role of
this transcript. Our study aimed to evaluate the expression
of PHF19-207 in colon cancer, as well as to investigate its
potential function using in silico tools.",
publisher = "Wiley",
journal = "Molecular oncology",
title = "Biomarker potential of the transcript PHF19-207 in colon cancer",
number = "Supplement 1",
pages = "70-70",
volume = "17",
doi = "doi.org/10.1002/1878-0261.13471"
}

Ignjatović, S., Pavlović, D., Babić, T., Dragičević, S.,& Nikolić, A.. (2023). Biomarker potential of the transcript PHF19-207 in colon cancer. in Molecular oncology
Wiley., 17(Supplement 1), 70.
https://doi.org/doi.org/10.1002/1878-0261.13471

Ignjatović S, Pavlović D, Babić T, Dragičević S, Nikolić A. Biomarker potential of the transcript PHF19-207 in colon cancer. in Molecular oncology. 2023;17(Supplement 1):70.
doi:doi.org/10.1002/1878-0261.13471 .

Ignjatović, Sofija, Pavlović, Dunja, Babić, Tamara, Dragičević, Sandra, Nikolić, Aleksandra, "Biomarker potential of the transcript PHF19-207 in colon cancer" in Molecular oncology, 17, no. Supplement 1 (2023):70,
https://doi.org/doi.org/10.1002/1878-0261.13471 . .

TY  - JOUR
AU  - Rosić, Jovana
AU  - Miladinov, Marko
AU  - Dragičević, Sandra
AU  - Erić, Katarina
AU  - Bogdanović, Aleksandar
AU  - Krivokapić, Zoran
AU  - Nikolić, Aleksandra
PY  - 2023
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1769
AB  - Considering the impact of SMAD7 deregulation in colorectal cancer (CRC) progression and the
significance of single nucleotide variant (SNV)-mediated disruptions of microRNA (miRNA)-dependent regulation
for cancer susceptibility, our study aimed to analyze genetic variation in the SMAD7 3′ untranslated region (
3′UTR) in CRC, measure differences in allelic mRNA expression, and evaluate its interference with miRNAmediated
post-transcriptional regulation.
Patients and Methods: This study included 80 patients with different CRC stages and six human colon cancer cell
lines of various histological origins. SMAD7 3′ UTR was analyzed by direct sequencing, followed by the relative
quantification of differential allelic expression of detected variants by allele-specific qRT-PCR. In silico tools were
employed for predictions of regulatory consequences of detected variants.
Results: A total of four different SNVs in one cell line and nine patients were found, among which were a novel
somatic point variant and three already known germline variants (rs16950113, rs1050799536, and
rs1043778717). All evaluated SNVs exhibited variable extents of allelic imbalance in expression. In silico analysis
predicted significant effects of SNVs on miRNA binding efficiency, with each SNV disrupting existing and
creating new target sites for one or more miRNAs.
Conclusion: Imbalance observed in the expression of SNV alleles altering miRNA binding suggests that all
investigated SNVs are potential contributing factors impacting SMAD7 expression regulation in CRC that further
studies should investigate.
PB  - Elsevier
T2  - Gene
T1  - Genetic analysis and allele-specific expression of SMAD7 3′UTR variants in human colorectal cancer reveal a novel somatic variant exhibiting allelic imbalance
SP  - 147217
VL  - 859
DO  - doi.org/10.1016/j.gene.2023.147217
ER  - 

@article{
author = "Rosić, Jovana and Miladinov, Marko and Dragičević, Sandra and Erić, Katarina and Bogdanović, Aleksandar and Krivokapić, Zoran and Nikolić, Aleksandra",
year = "2023",
abstract = "Considering the impact of SMAD7 deregulation in colorectal cancer (CRC) progression and the
significance of single nucleotide variant (SNV)-mediated disruptions of microRNA (miRNA)-dependent regulation
for cancer susceptibility, our study aimed to analyze genetic variation in the SMAD7 3′ untranslated region (
3′UTR) in CRC, measure differences in allelic mRNA expression, and evaluate its interference with miRNAmediated
post-transcriptional regulation.
Patients and Methods: This study included 80 patients with different CRC stages and six human colon cancer cell
lines of various histological origins. SMAD7 3′ UTR was analyzed by direct sequencing, followed by the relative
quantification of differential allelic expression of detected variants by allele-specific qRT-PCR. In silico tools were
employed for predictions of regulatory consequences of detected variants.
Results: A total of four different SNVs in one cell line and nine patients were found, among which were a novel
somatic point variant and three already known germline variants (rs16950113, rs1050799536, and
rs1043778717). All evaluated SNVs exhibited variable extents of allelic imbalance in expression. In silico analysis
predicted significant effects of SNVs on miRNA binding efficiency, with each SNV disrupting existing and
creating new target sites for one or more miRNAs.
Conclusion: Imbalance observed in the expression of SNV alleles altering miRNA binding suggests that all
investigated SNVs are potential contributing factors impacting SMAD7 expression regulation in CRC that further
studies should investigate.",
publisher = "Elsevier",
journal = "Gene",
title = "Genetic analysis and allele-specific expression of SMAD7 3′UTR variants in human colorectal cancer reveal a novel somatic variant exhibiting allelic imbalance",
pages = "147217",
volume = "859",
doi = "doi.org/10.1016/j.gene.2023.147217"
}

Rosić, J., Miladinov, M., Dragičević, S., Erić, K., Bogdanović, A., Krivokapić, Z.,& Nikolić, A.. (2023). Genetic analysis and allele-specific expression of SMAD7 3′UTR variants in human colorectal cancer reveal a novel somatic variant exhibiting allelic imbalance. in Gene
Elsevier., 859, 147217.
https://doi.org/doi.org/10.1016/j.gene.2023.147217

Rosić J, Miladinov M, Dragičević S, Erić K, Bogdanović A, Krivokapić Z, Nikolić A. Genetic analysis and allele-specific expression of SMAD7 3′UTR variants in human colorectal cancer reveal a novel somatic variant exhibiting allelic imbalance. in Gene. 2023;859:147217.
doi:doi.org/10.1016/j.gene.2023.147217 .

Rosić, Jovana, Miladinov, Marko, Dragičević, Sandra, Erić, Katarina, Bogdanović, Aleksandar, Krivokapić, Zoran, Nikolić, Aleksandra, "Genetic analysis and allele-specific expression of SMAD7 3′UTR variants in human colorectal cancer reveal a novel somatic variant exhibiting allelic imbalance" in Gene, 859 (2023):147217,
https://doi.org/doi.org/10.1016/j.gene.2023.147217 . .

TY  - JOUR
AU  - Nikolić, Aleksandra
AU  - Mark, Kevin J.
AU  - Dragičević, Sandra
AU  - Babić, Tamara
AU  - Milošević, Katarina
AU  - Nestorović, Branimir
AU  - Beskoski, Vladimir
PY  - 2023
UR  - https://www.eurekaselect.com/article/129606
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2058
AB  - Background: Leukocytes are key cellular effectors of inflammation in asthma and understandingtheir function in this disease is of crucial importance. Blood leukocytes reflect the actions oftheir counterparts in the lungs and they can be obtained through minimal invasive procedures as partof the peripheral blood.Objective: The aim of the study was to identify proteins in blood leukocyte proteomes that respond toex vivo treatment by prednisone in order to pinpoint candidates for predictive biomarkers in corticosteroid-responsive asthma.Methods: The study included five children diagnosed with asthma and five healthy children. After theex vivo treatment of blood samples with prednisone, lysis of erythrocytes was performed and proteinswere extracted from the remaining leukocytes by ultrasonic disintegration. Protein extracts were analyzedby reversed phase nano-liquidchromatography–tandem mass spectrometry (LC–MS/MS).Results: The stimulation of asthmatics' leukocytes with prednisone has led to an increase in the levelsof FYB (fold change 3.4) and LYZ (fold change 2.2) with a statistical significance of p
T2  - Current Proteomics
T1  - Pilot Study of the Ex Vivo Blood Leukocytes’ Proteomic Response to Prednisone Stimulation in Corticosteroid-responsive Asthma
EP  - 18
IS  - 1
SP  - 12
VL  - 20
DO  - 10.2174/1570164620666230220112500
ER  - 

@article{
author = "Nikolić, Aleksandra and Mark, Kevin J. and Dragičević, Sandra and Babić, Tamara and Milošević, Katarina and Nestorović, Branimir and Beskoski, Vladimir",
year = "2023",
abstract = "Background: Leukocytes are key cellular effectors of inflammation in asthma and understandingtheir function in this disease is of crucial importance. Blood leukocytes reflect the actions oftheir counterparts in the lungs and they can be obtained through minimal invasive procedures as partof the peripheral blood.Objective: The aim of the study was to identify proteins in blood leukocyte proteomes that respond toex vivo treatment by prednisone in order to pinpoint candidates for predictive biomarkers in corticosteroid-responsive asthma.Methods: The study included five children diagnosed with asthma and five healthy children. After theex vivo treatment of blood samples with prednisone, lysis of erythrocytes was performed and proteinswere extracted from the remaining leukocytes by ultrasonic disintegration. Protein extracts were analyzedby reversed phase nano-liquidchromatography–tandem mass spectrometry (LC–MS/MS).Results: The stimulation of asthmatics' leukocytes with prednisone has led to an increase in the levelsof FYB (fold change 3.4) and LYZ (fold change 2.2) with a statistical significance of p",
journal = "Current Proteomics",
title = "Pilot Study of the Ex Vivo Blood Leukocytes’ Proteomic Response to Prednisone Stimulation in Corticosteroid-responsive Asthma",
pages = "18-12",
number = "1",
volume = "20",
doi = "10.2174/1570164620666230220112500"
}

Nikolić, A., Mark, K. J., Dragičević, S., Babić, T., Milošević, K., Nestorović, B.,& Beskoski, V.. (2023). Pilot Study of the Ex Vivo Blood Leukocytes’ Proteomic Response to Prednisone Stimulation in Corticosteroid-responsive Asthma. in Current Proteomics, 20(1), 12-18.
https://doi.org/10.2174/1570164620666230220112500

Nikolić A, Mark KJ, Dragičević S, Babić T, Milošević K, Nestorović B, Beskoski V. Pilot Study of the Ex Vivo Blood Leukocytes’ Proteomic Response to Prednisone Stimulation in Corticosteroid-responsive Asthma. in Current Proteomics. 2023;20(1):12-18.
doi:10.2174/1570164620666230220112500 .

Nikolić, Aleksandra, Mark, Kevin J., Dragičević, Sandra, Babić, Tamara, Milošević, Katarina, Nestorović, Branimir, Beskoski, Vladimir, "Pilot Study of the Ex Vivo Blood Leukocytes’ Proteomic Response to Prednisone Stimulation in Corticosteroid-responsive Asthma" in Current Proteomics, 20, no. 1 (2023):12-18,
https://doi.org/10.2174/1570164620666230220112500 . .

TY  - JOUR
AU  - Jovanović, Ljubiša
AU  - Nikolić, Aleksandra
AU  - Dragičević, Sandra
AU  - Jović, Milena
AU  - Janković, Radmila
PY  - 2022
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2300
AB  - Aim To analyze the expression of autophagy markers p62,
LC3, and Beclin1 in ovarian cancer tissue and evaluate the
prognostic potential of these markers.
Methods The study enrolled 328 patients: 122 with epithelial ovarian carcinoma, 42 with atypical proliferative tumor, and 164 with benign epithelial ovarian tumor. The expression of p62, LC3, and Beclin1 was analyzed in central
and invasive tumor segments with immunohistochemistry
combined with tissue microarray. The expression levels of
the analyzed markers were correlated with relevant histopathology parameters.
Results The expression of all analyzed markers was most
remarkable in epithelial ovarian carcinoma. There was a
strong positive correlation between the expressions of p62
and LC3, while these two markers negatively correlated
with Beclin1. High-grade serous carcinoma had higher p62
and LC3 levels, and lower Beclin1 levels than other tumor
types. This expression profile was also observed in more
advanced tumor stages.
Conclusion Prominent p62 and LC3 expression in combination with weak Beclin1 expression in high-grade serous
carcinoma indicates potential for the application of autophagy inhibitors in patients with this tumor subtype.
PB  - Medicinska naklada (Croatia)
T2  - Croatian Medical Journal
T1  - Prognostic relevance of autophagy-related markers p62, LC3, and Beclin1 in ovarian cancer
EP  - 460
IS  - 5
SP  - 453
VL  - 63
DO  - 10.3325/cmj.2022.63.453
ER  - 

@article{
author = "Jovanović, Ljubiša and Nikolić, Aleksandra and Dragičević, Sandra and Jović, Milena and Janković, Radmila",
year = "2022",
abstract = "Aim To analyze the expression of autophagy markers p62,
LC3, and Beclin1 in ovarian cancer tissue and evaluate the
prognostic potential of these markers.
Methods The study enrolled 328 patients: 122 with epithelial ovarian carcinoma, 42 with atypical proliferative tumor, and 164 with benign epithelial ovarian tumor. The expression of p62, LC3, and Beclin1 was analyzed in central
and invasive tumor segments with immunohistochemistry
combined with tissue microarray. The expression levels of
the analyzed markers were correlated with relevant histopathology parameters.
Results The expression of all analyzed markers was most
remarkable in epithelial ovarian carcinoma. There was a
strong positive correlation between the expressions of p62
and LC3, while these two markers negatively correlated
with Beclin1. High-grade serous carcinoma had higher p62
and LC3 levels, and lower Beclin1 levels than other tumor
types. This expression profile was also observed in more
advanced tumor stages.
Conclusion Prominent p62 and LC3 expression in combination with weak Beclin1 expression in high-grade serous
carcinoma indicates potential for the application of autophagy inhibitors in patients with this tumor subtype.",
publisher = "Medicinska naklada (Croatia)",
journal = "Croatian Medical Journal",
title = "Prognostic relevance of autophagy-related markers p62, LC3, and Beclin1 in ovarian cancer",
pages = "460-453",
number = "5",
volume = "63",
doi = "10.3325/cmj.2022.63.453"
}

Jovanović, L., Nikolić, A., Dragičević, S., Jović, M.,& Janković, R.. (2022). Prognostic relevance of autophagy-related markers p62, LC3, and Beclin1 in ovarian cancer. in Croatian Medical Journal
Medicinska naklada (Croatia)., 63(5), 453-460.
https://doi.org/10.3325/cmj.2022.63.453

Jovanović L, Nikolić A, Dragičević S, Jović M, Janković R. Prognostic relevance of autophagy-related markers p62, LC3, and Beclin1 in ovarian cancer. in Croatian Medical Journal. 2022;63(5):453-460.
doi:10.3325/cmj.2022.63.453 .

Jovanović, Ljubiša, Nikolić, Aleksandra, Dragičević, Sandra, Jović, Milena, Janković, Radmila, "Prognostic relevance of autophagy-related markers p62, LC3, and Beclin1 in ovarian cancer" in Croatian Medical Journal, 63, no. 5 (2022):453-460,
https://doi.org/10.3325/cmj.2022.63.453 . .

TY  - CONF
AU  - Velimirov, Luka
AU  - Babić, Tamara
AU  - Dragičević, Sandra
AU  - Nikolić, Aleksandra
PY  - 2022
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2084
AB  - Gene LDLRAD4 plays a role in cell proliferation, apoptosis, immunosuppression and cancer
progression. Transcription of LDLRAD4 is regulated by several alternative promoters, two of which
were indicated by in silico analyses to be differentially active in rectal cancer. Promoter A encodes for a
truncated protein-coding transcript and is down-regulated in rectal cancer. Promoter B encodes for a
non-coding transcript up-regulated in rectal cancer identified as lnc-RNMT-2:5. The aim of this study
was to characterize the two alternative promoters in silico in order to explain their differential activity
and to investigate the profile of LDLRAD4 transcripts in colon cell lines. Nucleotide sequences used in
the analyses were downloaded from the Ensemble genome database (reference GRCh37). Three
bioinformatics tools were used for core promoter element prediction: GPMiner, YAPP and
CNNPromoter. Four bioinformatics tools were used for transcription factor binding site prediction:
PROMO, TFBIND, CiiiDER and Tfsitescan. Only the predictions made by two or more tools were
considered. Primer extension followed by fragment analysis was used to characterize LDLRAD4
transcripts present in colon cell lines. The promoter element predictions showed that the promoter A is
typical, while promoter B has most typical elements and lacks GC boxes. The transcription binding site
predictions indicate that three different transcription factors bind only to the promoter A (NF-kB,
EGR1 and IRF-7), while four different transcription factors bind only to the promoter B (HNF1,
POU2F1, POU2F2 and PTF1). The predicted transcription factors are mostly involved in regulation of
cell differentiation and proliferation. The primer extension experiment performed with primer specific
for exon 2-exon 3 junction produced multiple signals of relatively low intensity, indicating the presence
of multiple LDLRAD4 transcripts in colon cell lines. The results obtained by in silico analysis may
explain promoter B activation in rectal cancer. However, based on the results of primer extension, neither
of the LDLRAD4 transcripts is dominant in colon cell lines. Considering that promoter B generates
long non-coding RNA that can exert its function even at low expression level, it can serve as potential
colorectal cancer biomarker and its potential role in carcinogenesis should be investigated.
PB  - Croatian Association for Cancer Research, Zagreb, Croatia
C3  - “HDIR-6: Targeting Cancer” The 6th Meeting of the Croatian Association for Cancer Research with International Participation – Book of Abstracts
T1  - Analysis of Alternative LDLRAD4 Gene Promoters and Transcripts in Colorectal Cancer
EP  - 35
SP  - 35
UR  - https://hdl.handle.net/21.15107/rcub_imagine_2084
ER  - 

@conference{
author = "Velimirov, Luka and Babić, Tamara and Dragičević, Sandra and Nikolić, Aleksandra",
year = "2022",
abstract = "Gene LDLRAD4 plays a role in cell proliferation, apoptosis, immunosuppression and cancer
progression. Transcription of LDLRAD4 is regulated by several alternative promoters, two of which
were indicated by in silico analyses to be differentially active in rectal cancer. Promoter A encodes for a
truncated protein-coding transcript and is down-regulated in rectal cancer. Promoter B encodes for a
non-coding transcript up-regulated in rectal cancer identified as lnc-RNMT-2:5. The aim of this study
was to characterize the two alternative promoters in silico in order to explain their differential activity
and to investigate the profile of LDLRAD4 transcripts in colon cell lines. Nucleotide sequences used in
the analyses were downloaded from the Ensemble genome database (reference GRCh37). Three
bioinformatics tools were used for core promoter element prediction: GPMiner, YAPP and
CNNPromoter. Four bioinformatics tools were used for transcription factor binding site prediction:
PROMO, TFBIND, CiiiDER and Tfsitescan. Only the predictions made by two or more tools were
considered. Primer extension followed by fragment analysis was used to characterize LDLRAD4
transcripts present in colon cell lines. The promoter element predictions showed that the promoter A is
typical, while promoter B has most typical elements and lacks GC boxes. The transcription binding site
predictions indicate that three different transcription factors bind only to the promoter A (NF-kB,
EGR1 and IRF-7), while four different transcription factors bind only to the promoter B (HNF1,
POU2F1, POU2F2 and PTF1). The predicted transcription factors are mostly involved in regulation of
cell differentiation and proliferation. The primer extension experiment performed with primer specific
for exon 2-exon 3 junction produced multiple signals of relatively low intensity, indicating the presence
of multiple LDLRAD4 transcripts in colon cell lines. The results obtained by in silico analysis may
explain promoter B activation in rectal cancer. However, based on the results of primer extension, neither
of the LDLRAD4 transcripts is dominant in colon cell lines. Considering that promoter B generates
long non-coding RNA that can exert its function even at low expression level, it can serve as potential
colorectal cancer biomarker and its potential role in carcinogenesis should be investigated.",
publisher = "Croatian Association for Cancer Research, Zagreb, Croatia",
journal = "“HDIR-6: Targeting Cancer” The 6th Meeting of the Croatian Association for Cancer Research with International Participation – Book of Abstracts",
title = "Analysis of Alternative LDLRAD4 Gene Promoters and Transcripts in Colorectal Cancer",
pages = "35-35",
url = "https://hdl.handle.net/21.15107/rcub_imagine_2084"
}

Velimirov, L., Babić, T., Dragičević, S.,& Nikolić, A.. (2022). Analysis of Alternative LDLRAD4 Gene Promoters and Transcripts in Colorectal Cancer. in “HDIR-6: Targeting Cancer” The 6th Meeting of the Croatian Association for Cancer Research with International Participation – Book of Abstracts
Croatian Association for Cancer Research, Zagreb, Croatia., 35-35.
https://hdl.handle.net/21.15107/rcub_imagine_2084

Velimirov L, Babić T, Dragičević S, Nikolić A. Analysis of Alternative LDLRAD4 Gene Promoters and Transcripts in Colorectal Cancer. in “HDIR-6: Targeting Cancer” The 6th Meeting of the Croatian Association for Cancer Research with International Participation – Book of Abstracts. 2022;:35-35.
https://hdl.handle.net/21.15107/rcub_imagine_2084 .

Velimirov, Luka, Babić, Tamara, Dragičević, Sandra, Nikolić, Aleksandra, "Analysis of Alternative LDLRAD4 Gene Promoters and Transcripts in Colorectal Cancer" in “HDIR-6: Targeting Cancer” The 6th Meeting of the Croatian Association for Cancer Research with International Participation – Book of Abstracts (2022):35-35,
https://hdl.handle.net/21.15107/rcub_imagine_2084 .

TY  - CONF
AU  - Erić, K.
AU  - Miladinov, Marko
AU  - Dragičević, Sandra
AU  - Rosić, Jovana
AU  - Krivokapić, Zoran
AU  - Zeljić, Katarina
PY  - 2022
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2083
AB  - Background & objectives: Long non coding RNA, H19 is an imprinted, maternally expressed gene, usually deregulated in diferent cancer types, including rectal cancer. This study aimed to investigate H19 role as a potential biomarker to predict therapy response in rectal cancer patients. Methods: The study included 14 patients diagnosed with rectal cancer, treated with neoadjuvant chemoradio therapy (nCRT). RNA was isolated by TRIzol reagent from samples of rectal cancer tissue  before and after nCRT. Relative expression of H19 was normal- ized to housekeeping GAPDH gene, and expression was analysed  by quantitative real-time PCR. Relative expression of H19 was calculated by 2-ΔCt method. Results: Relative expression of H19 was significantly increased in rectal cancer tissue after nCRT (0.244±0.408) compared to the tissue before nCRT (0.043±0.055), p=0.004, Wilcoxon test. According to tumour regression grade (TRG), 85.71% (12/14) of  patients did not respond, while 14.28% (2/14) responded to pre- operative CRT. Responders (TRG1, TRG2) and non-responders  (TRG3, TRG4) did not differ in H19 expression in tumour tissue before (p=0.659, Mann-Whitney U test) as well as after nCRT  (p=0.999, Mann-Whitney U test). Receiver operating curve analy- sis indicates that H19 expression in colorectal tissue before nCRT  can not be used as a biomarker for distinguishing responders from non-responders (AUC=0.625, 95%CI=0.257-0.992, p=0.583).  Conclusion: Our study suggests H19 upregulation upon neoadju- vant chemoradiotherapy in rectal cancer. The potential predictive  value of H19 as a biomarker of therapy response should be studied in a larger group of patients.
PB  - Springer
C3  - Virchows Archiv, 34 th European Congress of Pathology - Abstracts
T1  - Long non-coding RNA H19 expression in rectal cancer and therapy response
EP  - S145
IS  - Supplement 1
SP  - S145
SP  - PS-15-017
VL  - 481
UR  - https://hdl.handle.net/21.15107/rcub_imagine_2083
ER  - 

@conference{
author = "Erić, K. and Miladinov, Marko and Dragičević, Sandra and Rosić, Jovana and Krivokapić, Zoran and Zeljić, Katarina",
year = "2022",
abstract = "Background & objectives: Long non coding RNA, H19 is an imprinted, maternally expressed gene, usually deregulated in diferent cancer types, including rectal cancer. This study aimed to investigate H19 role as a potential biomarker to predict therapy response in rectal cancer patients. Methods: The study included 14 patients diagnosed with rectal cancer, treated with neoadjuvant chemoradio therapy (nCRT). RNA was isolated by TRIzol reagent from samples of rectal cancer tissue  before and after nCRT. Relative expression of H19 was normal- ized to housekeeping GAPDH gene, and expression was analysed  by quantitative real-time PCR. Relative expression of H19 was calculated by 2-ΔCt method. Results: Relative expression of H19 was significantly increased in rectal cancer tissue after nCRT (0.244±0.408) compared to the tissue before nCRT (0.043±0.055), p=0.004, Wilcoxon test. According to tumour regression grade (TRG), 85.71% (12/14) of  patients did not respond, while 14.28% (2/14) responded to pre- operative CRT. Responders (TRG1, TRG2) and non-responders  (TRG3, TRG4) did not differ in H19 expression in tumour tissue before (p=0.659, Mann-Whitney U test) as well as after nCRT  (p=0.999, Mann-Whitney U test). Receiver operating curve analy- sis indicates that H19 expression in colorectal tissue before nCRT  can not be used as a biomarker for distinguishing responders from non-responders (AUC=0.625, 95%CI=0.257-0.992, p=0.583).  Conclusion: Our study suggests H19 upregulation upon neoadju- vant chemoradiotherapy in rectal cancer. The potential predictive  value of H19 as a biomarker of therapy response should be studied in a larger group of patients.",
publisher = "Springer",
journal = "Virchows Archiv, 34 th European Congress of Pathology - Abstracts",
title = "Long non-coding RNA H19 expression in rectal cancer and therapy response",
pages = "S145-S145-PS-15-017",
number = "Supplement 1",
volume = "481",
url = "https://hdl.handle.net/21.15107/rcub_imagine_2083"
}

Erić, K., Miladinov, M., Dragičević, S., Rosić, J., Krivokapić, Z.,& Zeljić, K.. (2022). Long non-coding RNA H19 expression in rectal cancer and therapy response. in Virchows Archiv, 34 th European Congress of Pathology - Abstracts
Springer., 481(Supplement 1), S145-S145.
https://hdl.handle.net/21.15107/rcub_imagine_2083

Erić K, Miladinov M, Dragičević S, Rosić J, Krivokapić Z, Zeljić K. Long non-coding RNA H19 expression in rectal cancer and therapy response. in Virchows Archiv, 34 th European Congress of Pathology - Abstracts. 2022;481(Supplement 1):S145-S145.
https://hdl.handle.net/21.15107/rcub_imagine_2083 .

Erić, K., Miladinov, Marko, Dragičević, Sandra, Rosić, Jovana, Krivokapić, Zoran, Zeljić, Katarina, "Long non-coding RNA H19 expression in rectal cancer and therapy response" in Virchows Archiv, 34 th European Congress of Pathology - Abstracts, 481, no. Supplement 1 (2022):S145-S145,
https://hdl.handle.net/21.15107/rcub_imagine_2083 .

TY  - CONF
AU  - Jovanović, I.
AU  - Nikolić, Aleksandra
AU  - Dragičević, Sandra
AU  - Jović, M.
AU  - Janković, R.
PY  - 2022
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2082
AB  - Background & objectives: Autophagy is a crucial cellular mechanism that coordinates various physiological processes. Many cancers can activate autophagy and make the tumour more aggressive. In this study, we analysed autophagy in ovarian cancers. Methods: We included 122 patients with ovarian cancers. Tissue microarray was made for immunohistochemical analysis of p62, LC3, and Beclin1 expressions. Their expressions were correlated with tumour histology type, differentiation, and stage. The percentage of positive tumour cells was estimated from the total number of tumour cells. Samples with positive cells were stratified into three ranges of positivity: <10%; 10–50%; >50%. Results: There was a strong positive correlation between p62 and LC3 expression, while both markers were in negative correlation with Beclin1. The expression of each analysed marker showed a statistically significant association with tumour histological type, stage, and differentiation (p<0.001). While p62 and LC3 were more prominently expressed in patients with high-grade serous ovarian cancer (HGSOC), Beclin 1 expression was lower in HGSOC and more prominent in other histology types. A higher expression of  p62 and LC3 was observed in later tumour stages, while the oppo- site was observed for Beclin1 expression. Tumour differentiation  positively correlated with p62 and LC3 expression, and negatively with Beclin1 expression.  Conclusion: The expression of p62 and LC3 was more promi- nent in HGSOC in comparison to other histology types, while  Beclin1 expression was more prominent in carcinomas other than in HGSOC. While p62 and LC3 expression was associated with higher tumour stages and tumour grades, the opposite was found for Beclin1. Prominent p62 and LC3 expression in combination with weak Beclin1 expression in HGSOC indicate the potential for application of autophagy inhibitors in patients with this tumour subtype.
PB  - Springer
C3  - Virchows Archiv, 34 th European Congress of Pathology - Abstracts
T1  - Expression of autophagy markers in ovarian cancer
EP  - S256
IS  - Supplement 1
SP  - S256
SP  - E-PS-09-003
VL  - 481
UR  - https://hdl.handle.net/21.15107/rcub_imagine_2082
ER  - 

@conference{
author = "Jovanović, I. and Nikolić, Aleksandra and Dragičević, Sandra and Jović, M. and Janković, R.",
year = "2022",
abstract = "Background & objectives: Autophagy is a crucial cellular mechanism that coordinates various physiological processes. Many cancers can activate autophagy and make the tumour more aggressive. In this study, we analysed autophagy in ovarian cancers. Methods: We included 122 patients with ovarian cancers. Tissue microarray was made for immunohistochemical analysis of p62, LC3, and Beclin1 expressions. Their expressions were correlated with tumour histology type, differentiation, and stage. The percentage of positive tumour cells was estimated from the total number of tumour cells. Samples with positive cells were stratified into three ranges of positivity: <10%; 10–50%; >50%. Results: There was a strong positive correlation between p62 and LC3 expression, while both markers were in negative correlation with Beclin1. The expression of each analysed marker showed a statistically significant association with tumour histological type, stage, and differentiation (p<0.001). While p62 and LC3 were more prominently expressed in patients with high-grade serous ovarian cancer (HGSOC), Beclin 1 expression was lower in HGSOC and more prominent in other histology types. A higher expression of  p62 and LC3 was observed in later tumour stages, while the oppo- site was observed for Beclin1 expression. Tumour differentiation  positively correlated with p62 and LC3 expression, and negatively with Beclin1 expression.  Conclusion: The expression of p62 and LC3 was more promi- nent in HGSOC in comparison to other histology types, while  Beclin1 expression was more prominent in carcinomas other than in HGSOC. While p62 and LC3 expression was associated with higher tumour stages and tumour grades, the opposite was found for Beclin1. Prominent p62 and LC3 expression in combination with weak Beclin1 expression in HGSOC indicate the potential for application of autophagy inhibitors in patients with this tumour subtype.",
publisher = "Springer",
journal = "Virchows Archiv, 34 th European Congress of Pathology - Abstracts",
title = "Expression of autophagy markers in ovarian cancer",
pages = "S256-S256-E-PS-09-003",
number = "Supplement 1",
volume = "481",
url = "https://hdl.handle.net/21.15107/rcub_imagine_2082"
}

Jovanović, I., Nikolić, A., Dragičević, S., Jović, M.,& Janković, R.. (2022). Expression of autophagy markers in ovarian cancer. in Virchows Archiv, 34 th European Congress of Pathology - Abstracts
Springer., 481(Supplement 1), S256-S256.
https://hdl.handle.net/21.15107/rcub_imagine_2082

Jovanović I, Nikolić A, Dragičević S, Jović M, Janković R. Expression of autophagy markers in ovarian cancer. in Virchows Archiv, 34 th European Congress of Pathology - Abstracts. 2022;481(Supplement 1):S256-S256.
https://hdl.handle.net/21.15107/rcub_imagine_2082 .

Jovanović, I., Nikolić, Aleksandra, Dragičević, Sandra, Jović, M., Janković, R., "Expression of autophagy markers in ovarian cancer" in Virchows Archiv, 34 th European Congress of Pathology - Abstracts, 481, no. Supplement 1 (2022):S256-S256,
https://hdl.handle.net/21.15107/rcub_imagine_2082 .

TY  - CONF
AU  - Jovanović, Emilija
AU  - Dragičević, Sandra
AU  - Babić, Tamara
AU  - Nikolić, Aleksandra
PY  - 2022
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1741
AB  - Transkripcija gena CD81, čiji proteinski produkt ostvaruje brojne biološke
uloge i uključen je u razvoj maligniteta, regulisana je alternativnim
promotorima. U prethodnoj in silico studiji pokazali smo da se regulatorni
proteini diferencijalno vezuju za alternativne promotore gena CD81 označene
kao A i B, za koje je prethodno pokazano da su diferencijalno aktivni u
kolorektalnom karcinomu.1,2 Cilj ovog rada bio je da se u kolorektalnom
karcinomu in vitro analiziraju transkripti koji nastaju usled aktivnosti ovih
promotora. Ekspresija alternativnih transkripata, kao i ukupna ekspresija gena
CD81 analizirane su u humanim ćelijskim linijama kolona metodom PCR u
realnom vremenu. Pokazano je da alternativni promotori doprinose ukupnoj
ekspresiji gena CD81 sa relativno malim udelom: promotor A 0,43-12,86%, a
promotor B 0,40-4,13%. U nemalignoj ćelijskoj liniji HCEC-1CT, pokazan je
približno jednak nivo ekspresije transkripata oba promotora, dok je u malignim
ćelijskim linijama HT29, Caco-2, HCT116, SW480 i SW620, ekspresija
transkipata promotora A bila veća u odnosu na promotor B, što je očekivano na
osnovu prethodnih in silico studija. Dobijeni rezultati ukazuju na potencijal
alternativnih transkripata gena CD81 kao biomarkera za kolorektalni karcinom.
Kako uloga transkripata nije poznata, njihova struktura i ekspresija sugerišu da
treba ispitati mogućnost da neki od njih mogu biti duge nekodirajuće RNK.
AB  - Транскрипција гена CD81, чији протеински продукт остварује бројне биолошке
улоге и укључен је у развој малигнитета, регулисана је алтернативним
промоторима. У претходној in silico студији показали смо да се регулаторни
протеини диференцијално везују за алтернативне промоторе гена CD81 означене
као А и Б, за које је претходно показано да су диференцијално активни у
колоректалном карциному.1,2 Циљ овог рада био је да се у колоректалном
карциному in vitro анализирају транскрипти који настају услед активности ових
промотора. Експресија алтернативних транскрипата, као и укупна експресија гена
CD81 анализиране су у хуманим ћелијским линијама колона методом ПЦР у
реaлном времену. Показано је да алтернативни промотори доприносе укупној
експресији гена CD81 са релативно малим уделом: промотор А 0,43-12,86%, а
промотор Б 0,40-4,13%. У немалигној ћелијској линији HCEC-1CT, показан је
приближно једнак ниво експресије транскрипата оба промотора, док је у малигним
ћелијским линијама HT29, Caco-2, HCT116, SW480 и SW620, експресија
транскипата промотора А била већа у односу на промотор Б, што је очекивано на
основу претходних in silico студија. Добијени резултати указују на потенцијал
алтернативних транскрипата гена CD81 као биомаркера за колоректални карцином.
Како улога транскрипата није позната, њихова структура и експресија сугеришу да
треба испитати могућност да неки од њих могу бити дуге некодирајуће РНК.
PB  - Treći kongres biologa Srbije
C3  - Treći kongres biologa Srbije
T1  - Analiza alternativnih transkripata gena CD81 u kolorektalnom karcinomu
T1  - Анализа алтернативних транскрипата гена CD81 у колоректалном карциному
EP  - 303
SP  - 303
UR  - https://hdl.handle.net/21.15107/rcub_imagine_1741
ER  - 

@conference{
author = "Jovanović, Emilija and Dragičević, Sandra and Babić, Tamara and Nikolić, Aleksandra",
year = "2022",
abstract = "Transkripcija gena CD81, čiji proteinski produkt ostvaruje brojne biološke
uloge i uključen je u razvoj maligniteta, regulisana je alternativnim
promotorima. U prethodnoj in silico studiji pokazali smo da se regulatorni
proteini diferencijalno vezuju za alternativne promotore gena CD81 označene
kao A i B, za koje je prethodno pokazano da su diferencijalno aktivni u
kolorektalnom karcinomu.1,2 Cilj ovog rada bio je da se u kolorektalnom
karcinomu in vitro analiziraju transkripti koji nastaju usled aktivnosti ovih
promotora. Ekspresija alternativnih transkripata, kao i ukupna ekspresija gena
CD81 analizirane su u humanim ćelijskim linijama kolona metodom PCR u
realnom vremenu. Pokazano je da alternativni promotori doprinose ukupnoj
ekspresiji gena CD81 sa relativno malim udelom: promotor A 0,43-12,86%, a
promotor B 0,40-4,13%. U nemalignoj ćelijskoj liniji HCEC-1CT, pokazan je
približno jednak nivo ekspresije transkripata oba promotora, dok je u malignim
ćelijskim linijama HT29, Caco-2, HCT116, SW480 i SW620, ekspresija
transkipata promotora A bila veća u odnosu na promotor B, što je očekivano na
osnovu prethodnih in silico studija. Dobijeni rezultati ukazuju na potencijal
alternativnih transkripata gena CD81 kao biomarkera za kolorektalni karcinom.
Kako uloga transkripata nije poznata, njihova struktura i ekspresija sugerišu da
treba ispitati mogućnost da neki od njih mogu biti duge nekodirajuće RNK., Транскрипција гена CD81, чији протеински продукт остварује бројне биолошке
улоге и укључен је у развој малигнитета, регулисана је алтернативним
промоторима. У претходној in silico студији показали смо да се регулаторни
протеини диференцијално везују за алтернативне промоторе гена CD81 означене
као А и Б, за које је претходно показано да су диференцијално активни у
колоректалном карциному.1,2 Циљ овог рада био је да се у колоректалном
карциному in vitro анализирају транскрипти који настају услед активности ових
промотора. Експресија алтернативних транскрипата, као и укупна експресија гена
CD81 анализиране су у хуманим ћелијским линијама колона методом ПЦР у
реaлном времену. Показано је да алтернативни промотори доприносе укупној
експресији гена CD81 са релативно малим уделом: промотор А 0,43-12,86%, а
промотор Б 0,40-4,13%. У немалигној ћелијској линији HCEC-1CT, показан је
приближно једнак ниво експресије транскрипата оба промотора, док је у малигним
ћелијским линијама HT29, Caco-2, HCT116, SW480 и SW620, експресија
транскипата промотора А била већа у односу на промотор Б, што је очекивано на
основу претходних in silico студија. Добијени резултати указују на потенцијал
алтернативних транскрипата гена CD81 као биомаркера за колоректални карцином.
Како улога транскрипата није позната, њихова структура и експресија сугеришу да
треба испитати могућност да неки од њих могу бити дуге некодирајуће РНК.",
publisher = "Treći kongres biologa Srbije",
journal = "Treći kongres biologa Srbije",
title = "Analiza alternativnih transkripata gena CD81 u kolorektalnom karcinomu, Анализа алтернативних транскрипата гена CD81 у колоректалном карциному",
pages = "303-303",
url = "https://hdl.handle.net/21.15107/rcub_imagine_1741"
}

Jovanović, E., Dragičević, S., Babić, T.,& Nikolić, A.. (2022). Analiza alternativnih transkripata gena CD81 u kolorektalnom karcinomu. in Treći kongres biologa Srbije
Treći kongres biologa Srbije., 303-303.
https://hdl.handle.net/21.15107/rcub_imagine_1741

Jovanović E, Dragičević S, Babić T, Nikolić A. Analiza alternativnih transkripata gena CD81 u kolorektalnom karcinomu. in Treći kongres biologa Srbije. 2022;:303-303.
https://hdl.handle.net/21.15107/rcub_imagine_1741 .

Jovanović, Emilija, Dragičević, Sandra, Babić, Tamara, Nikolić, Aleksandra, "Analiza alternativnih transkripata gena CD81 u kolorektalnom karcinomu" in Treći kongres biologa Srbije (2022):303-303,
https://hdl.handle.net/21.15107/rcub_imagine_1741 .

TY  - JOUR
AU  - Despotović, Jovana
AU  - Bogdanović, Aleksandar
AU  - Dragičević, Sandra
AU  - Galun, Danijel
AU  - Krivokapić, Zoran
AU  - Nikolić, Aleksandra
PY  - 2022
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1588
AB  - This study aimed to examine the expression pattern of tumoral and circulating miR-93-5p in patients with colorectal cancer (CRC) liver metastasis (CRLM) and to explore its predictive and prognostic potential. CRLM tissue, surrounding non-tumor liver tissue, and serum were obtained from 35 patients with CRLM. The expression pattern of tissue and circulating miR-93-5p in patients with CRLM was determined using quantitative polymerase chain reaction, using miR-16-5p for normalization. Sample-based cut-off values for CRLM and serum miR-93-5p expression were calculated using Receiver Operating Characteristic curve analysis to stratify the patients into high and low miR-93-5p expression groups which were that compared with patients??? clinicopathological data, therapy response, one-year disease-free survival, and disease recurrence. Relative miR-93-5p expression was higher in CRLM in comparison to the non-metastatic liver tissue (p lt 0.001). CRLM miR-93-5p expression showed moderate negative correlation with carcinoembryonic antigen levels (r=???0.406; p=0.016). There were no differences in high-/low-miR-93-5p expression and therapy responders vs. non-responders, which was confirmed in vitro using metastatic and normal colonic cells SW620 and HCEC-1CT, respectively. No difference was observed in one-year recurrence-free survival in patients with high vs. low miR-93-5p expression in CRLM or serum. However, high miR-93-5p serum levels were significantly associated with early disease recurrence (p=0.035). In conclusion, miR-93-5p serum levels could be potentially used as a prognostic factor for early disease recurrence in CRLM patients.
PB  - Aepress Sro, Bratislava
T2  - Neoplasma
T1  - Prognostic potential of circulating miR-93-5p in patients with colorectal cancer liver metastases
EP  - 442
IS  - 2
SP  - 430
VL  - 69
DO  - 10.4149/neo_2021_210603N749
ER  - 

@article{
author = "Despotović, Jovana and Bogdanović, Aleksandar and Dragičević, Sandra and Galun, Danijel and Krivokapić, Zoran and Nikolić, Aleksandra",
year = "2022",
abstract = "This study aimed to examine the expression pattern of tumoral and circulating miR-93-5p in patients with colorectal cancer (CRC) liver metastasis (CRLM) and to explore its predictive and prognostic potential. CRLM tissue, surrounding non-tumor liver tissue, and serum were obtained from 35 patients with CRLM. The expression pattern of tissue and circulating miR-93-5p in patients with CRLM was determined using quantitative polymerase chain reaction, using miR-16-5p for normalization. Sample-based cut-off values for CRLM and serum miR-93-5p expression were calculated using Receiver Operating Characteristic curve analysis to stratify the patients into high and low miR-93-5p expression groups which were that compared with patients??? clinicopathological data, therapy response, one-year disease-free survival, and disease recurrence. Relative miR-93-5p expression was higher in CRLM in comparison to the non-metastatic liver tissue (p lt 0.001). CRLM miR-93-5p expression showed moderate negative correlation with carcinoembryonic antigen levels (r=???0.406; p=0.016). There were no differences in high-/low-miR-93-5p expression and therapy responders vs. non-responders, which was confirmed in vitro using metastatic and normal colonic cells SW620 and HCEC-1CT, respectively. No difference was observed in one-year recurrence-free survival in patients with high vs. low miR-93-5p expression in CRLM or serum. However, high miR-93-5p serum levels were significantly associated with early disease recurrence (p=0.035). In conclusion, miR-93-5p serum levels could be potentially used as a prognostic factor for early disease recurrence in CRLM patients.",
publisher = "Aepress Sro, Bratislava",
journal = "Neoplasma",
title = "Prognostic potential of circulating miR-93-5p in patients with colorectal cancer liver metastases",
pages = "442-430",
number = "2",
volume = "69",
doi = "10.4149/neo_2021_210603N749"
}

Despotović, J., Bogdanović, A., Dragičević, S., Galun, D., Krivokapić, Z.,& Nikolić, A.. (2022). Prognostic potential of circulating miR-93-5p in patients with colorectal cancer liver metastases. in Neoplasma
Aepress Sro, Bratislava., 69(2), 430-442.
https://doi.org/10.4149/neo_2021_210603N749

Despotović J, Bogdanović A, Dragičević S, Galun D, Krivokapić Z, Nikolić A. Prognostic potential of circulating miR-93-5p in patients with colorectal cancer liver metastases. in Neoplasma. 2022;69(2):430-442.
doi:10.4149/neo_2021_210603N749 .

Despotović, Jovana, Bogdanović, Aleksandar, Dragičević, Sandra, Galun, Danijel, Krivokapić, Zoran, Nikolić, Aleksandra, "Prognostic potential of circulating miR-93-5p in patients with colorectal cancer liver metastases" in Neoplasma, 69, no. 2 (2022):430-442,
https://doi.org/10.4149/neo_2021_210603N749 . .

TY  - JOUR
AU  - Jendrišek, Gorana
AU  - Nikolić, Aleksandra
AU  - Dragičević, Sandra
PY  - 2022
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1512
AB  - Montelukast, a leukotriene receptor antagonist, is the most prescribed nonsteroidal anti-inflammatory drug used as an add-on therapy for asthma. Besides its effect on blocking leukotriene action, montelukast has been proposed to have secondary anti-inflammatory properties. This study aimed to investigate the modulatory effect of montelukast on the expression of major genes involved in airway inflammation (TNF, IL6) and remodeling (MMP9, TGFB1) in response to lipopolysaccharide (LPS) in vitro. The expression of selected genes was measured by quantitative real-time polymerase chain reaction 0h and 24h after LPS stimulation in cells pretreated with montelukast. Montelukast was found to significantly attenuate increased TNF and IL6 gene expression, to have a mild effect on MMP9 and have no effect on TGFB1 expression upon stimulation with LPS. The results of our study indicate that patients on montelukast therapy would have an adequate response to acute microorganism-induced inflammation, so additional anti-inflammatory effects of montelukast should be better exploited.
PB  - Univerzitet u Kragujevcu - Prirodno-matematički fakultet, Kragujevac
T2  - Kragujevac Journal of Science
T1  - Inflammatory modulation of the response of bronchial epithelial cells to lipopolysaccharide with pretreatment by montelukast
EP  - 125
IS  - 44
SP  - 115
DO  - 10.5937/KgJSci2244115J
ER  - 

@article{
author = "Jendrišek, Gorana and Nikolić, Aleksandra and Dragičević, Sandra",
year = "2022",
abstract = "Montelukast, a leukotriene receptor antagonist, is the most prescribed nonsteroidal anti-inflammatory drug used as an add-on therapy for asthma. Besides its effect on blocking leukotriene action, montelukast has been proposed to have secondary anti-inflammatory properties. This study aimed to investigate the modulatory effect of montelukast on the expression of major genes involved in airway inflammation (TNF, IL6) and remodeling (MMP9, TGFB1) in response to lipopolysaccharide (LPS) in vitro. The expression of selected genes was measured by quantitative real-time polymerase chain reaction 0h and 24h after LPS stimulation in cells pretreated with montelukast. Montelukast was found to significantly attenuate increased TNF and IL6 gene expression, to have a mild effect on MMP9 and have no effect on TGFB1 expression upon stimulation with LPS. The results of our study indicate that patients on montelukast therapy would have an adequate response to acute microorganism-induced inflammation, so additional anti-inflammatory effects of montelukast should be better exploited.",
publisher = "Univerzitet u Kragujevcu - Prirodno-matematički fakultet, Kragujevac",
journal = "Kragujevac Journal of Science",
title = "Inflammatory modulation of the response of bronchial epithelial cells to lipopolysaccharide with pretreatment by montelukast",
pages = "125-115",
number = "44",
doi = "10.5937/KgJSci2244115J"
}

Jendrišek, G., Nikolić, A.,& Dragičević, S.. (2022). Inflammatory modulation of the response of bronchial epithelial cells to lipopolysaccharide with pretreatment by montelukast. in Kragujevac Journal of Science
Univerzitet u Kragujevcu - Prirodno-matematički fakultet, Kragujevac.(44), 115-125.
https://doi.org/10.5937/KgJSci2244115J

Jendrišek G, Nikolić A, Dragičević S. Inflammatory modulation of the response of bronchial epithelial cells to lipopolysaccharide with pretreatment by montelukast. in Kragujevac Journal of Science. 2022;(44):115-125.
doi:10.5937/KgJSci2244115J .

Jendrišek, Gorana, Nikolić, Aleksandra, Dragičević, Sandra, "Inflammatory modulation of the response of bronchial epithelial cells to lipopolysaccharide with pretreatment by montelukast" in Kragujevac Journal of Science, no. 44 (2022):115-125,
https://doi.org/10.5937/KgJSci2244115J . .

TY  - JOUR
AU  - Babić, Tamara
AU  - Dragičević, Sandra
AU  - Miladinov, Marko
AU  - Krivokapić, Zoran
AU  - Nikolić, Aleksandra
PY  - 2022
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1532
AB  - Background: Transcripts with alternative 5'-untranslated regions (UTRs) result from the activity of alternative promoters and they can determine gene expression by influencing its stability and translational efficiency, thus executing complex regulation of developmental, physiological and pathological processes. Transcriptional regulation of human SMAD4, a key tumor suppressor deregulated in most gastrointestinal cancers, entails four alternative promoters. These promoters and alternative transcripts they generate remain unexplored as contributors to the SMAD4 deregulation in cancer. The aim of this study was to investigate the relative abundance of the transcript SMAD4-201 in colorectal cell lines and tissues in order to establish if its fluctuations may be associated with colorectal cancer (CRC). Methods: Relative abundance of SMAD4-201 in total SMAD4 mRNA was analyzed using quantitative PCR in a set of permanent human colon cell lines and tumor and corresponding healthy tissue samples from patients with CRC. Results: The relative abundance of SMAD4-201 in analyzed cell lines varied between 16 and 47%. A similar relative abundance of SMAD4-201 transcript was found in the majority of analyzed human tumor tissue samples, and it was averagely 20% lower in non-malignant in comparison to malignant tissue samples (p = 0.001). Transcript SMAD4-202 was not detectable in any of the analyzed samples, so the observed fluctuations in the composition of SMAD4 transcripts can be attributed to transcripts other than SMAD4-201 and SMAD4-202. Conclusion: The expression profile of SMAD4-201 in human tumor and non-tumor tissue samples may indicate the translational potential of this molecule in CRC, but further research is needed to clarify its usability as a potential biomarker for early diagnosis.
PB  - BMC, London
T2  - Bmc Cancer
T1  - SMAD4-201 transcript as a putative biomarker in colorectal cancer
IS  - 1
VL  - 22
DO  - 10.1186/s12885-022-09186-z
ER  - 

@article{
author = "Babić, Tamara and Dragičević, Sandra and Miladinov, Marko and Krivokapić, Zoran and Nikolić, Aleksandra",
year = "2022",
abstract = "Background: Transcripts with alternative 5'-untranslated regions (UTRs) result from the activity of alternative promoters and they can determine gene expression by influencing its stability and translational efficiency, thus executing complex regulation of developmental, physiological and pathological processes. Transcriptional regulation of human SMAD4, a key tumor suppressor deregulated in most gastrointestinal cancers, entails four alternative promoters. These promoters and alternative transcripts they generate remain unexplored as contributors to the SMAD4 deregulation in cancer. The aim of this study was to investigate the relative abundance of the transcript SMAD4-201 in colorectal cell lines and tissues in order to establish if its fluctuations may be associated with colorectal cancer (CRC). Methods: Relative abundance of SMAD4-201 in total SMAD4 mRNA was analyzed using quantitative PCR in a set of permanent human colon cell lines and tumor and corresponding healthy tissue samples from patients with CRC. Results: The relative abundance of SMAD4-201 in analyzed cell lines varied between 16 and 47%. A similar relative abundance of SMAD4-201 transcript was found in the majority of analyzed human tumor tissue samples, and it was averagely 20% lower in non-malignant in comparison to malignant tissue samples (p = 0.001). Transcript SMAD4-202 was not detectable in any of the analyzed samples, so the observed fluctuations in the composition of SMAD4 transcripts can be attributed to transcripts other than SMAD4-201 and SMAD4-202. Conclusion: The expression profile of SMAD4-201 in human tumor and non-tumor tissue samples may indicate the translational potential of this molecule in CRC, but further research is needed to clarify its usability as a potential biomarker for early diagnosis.",
publisher = "BMC, London",
journal = "Bmc Cancer",
title = "SMAD4-201 transcript as a putative biomarker in colorectal cancer",
number = "1",
volume = "22",
doi = "10.1186/s12885-022-09186-z"
}

Babić, T., Dragičević, S., Miladinov, M., Krivokapić, Z.,& Nikolić, A.. (2022). SMAD4-201 transcript as a putative biomarker in colorectal cancer. in Bmc Cancer
BMC, London., 22(1).
https://doi.org/10.1186/s12885-022-09186-z

Babić T, Dragičević S, Miladinov M, Krivokapić Z, Nikolić A. SMAD4-201 transcript as a putative biomarker in colorectal cancer. in Bmc Cancer. 2022;22(1).
doi:10.1186/s12885-022-09186-z .

Babić, Tamara, Dragičević, Sandra, Miladinov, Marko, Krivokapić, Zoran, Nikolić, Aleksandra, "SMAD4-201 transcript as a putative biomarker in colorectal cancer" in Bmc Cancer, 22, no. 1 (2022),
https://doi.org/10.1186/s12885-022-09186-z . .

TY  - CONF
AU  - Babić, Tamara
AU  - Dragičević, Sandra
AU  - Miladinov, Marko
AU  - Krivokapić, Zoran
AU  - Nikolić, Aleksandra
PY  - 2022
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1563
PB  - Springernature, London
C3  - European Journal of Human Genetics
T1  - SMAD4 gene coding transcripts with alternative 5 ' ends as colorectal cancer biomarkers
EP  - 556
IS  - SUPPL 1
SP  - 556
VL  - 30
UR  - https://hdl.handle.net/21.15107/rcub_imagine_1563
ER  - 

@conference{
author = "Babić, Tamara and Dragičević, Sandra and Miladinov, Marko and Krivokapić, Zoran and Nikolić, Aleksandra",
year = "2022",
publisher = "Springernature, London",
journal = "European Journal of Human Genetics",
title = "SMAD4 gene coding transcripts with alternative 5 ' ends as colorectal cancer biomarkers",
pages = "556-556",
number = "SUPPL 1",
volume = "30",
url = "https://hdl.handle.net/21.15107/rcub_imagine_1563"
}

Babić, T., Dragičević, S., Miladinov, M., Krivokapić, Z.,& Nikolić, A.. (2022). SMAD4 gene coding transcripts with alternative 5 ' ends as colorectal cancer biomarkers. in European Journal of Human Genetics
Springernature, London., 30(SUPPL 1), 556-556.
https://hdl.handle.net/21.15107/rcub_imagine_1563

Babić T, Dragičević S, Miladinov M, Krivokapić Z, Nikolić A. SMAD4 gene coding transcripts with alternative 5 ' ends as colorectal cancer biomarkers. in European Journal of Human Genetics. 2022;30(SUPPL 1):556-556.
https://hdl.handle.net/21.15107/rcub_imagine_1563 .

Babić, Tamara, Dragičević, Sandra, Miladinov, Marko, Krivokapić, Zoran, Nikolić, Aleksandra, "SMAD4 gene coding transcripts with alternative 5 ' ends as colorectal cancer biomarkers" in European Journal of Human Genetics, 30, no. SUPPL 1 (2022):556-556,
https://hdl.handle.net/21.15107/rcub_imagine_1563 .

TY  - JOUR
AU  - Ugrin, Milena
AU  - Dinić, Jelena
AU  - Jeremić, Sanja
AU  - Dragičević, Sandra
AU  - Banović Đeri, Bojana
AU  - Nikolić, Aleksandra
PY  - 2021
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1478
AB  - Bacterial nanocellulose (BNC) stands out among polymers as a promising biomaterial due to its mechanical strength, hydrophilicity, biocompatibility, biodegradability, low toxicity and renewability. The use of scaffolds based on BNC for 3D cell culture has been previously demonstrated. The study exploited excellent properties of the BNC to develop an efficient and low-cost in vitro cell migration assay. The BNC scaffold was introduced into a cell culture 24 h after the SW480 cells were seeded, and cells were allowed to enter the scaffold within the next 24-48 h. The cells were stained with different fluorophores either before or after the introduction of the scaffold in the culture. Untreated cells were observed to enter the BNC scaffold in significant numbers, form clusters and retain a high viability after 48 h. To validate the assay's usability for drug development, the treatments of SW480 cells were performed using aspirin, an agent known to reduce the migratory potential of this cell line in culture. This study demonstrates the application of BNC as a scaffold for cell migration testing as a low-cost alternative to commercial assays based on the Boyden chamber principle. The assay could be further developed for routine use in cancer research and anticancer drug development.
PB  - MDPI, Basel
T2  - Nanomaterials
T1  - Bacterial Nanocellulose as a Scaffold for In Vitro Cell Migration Assay
IS  - 9
VL  - 11
DO  - 10.3390/nano11092322
ER  - 

@article{
author = "Ugrin, Milena and Dinić, Jelena and Jeremić, Sanja and Dragičević, Sandra and Banović Đeri, Bojana and Nikolić, Aleksandra",
year = "2021",
abstract = "Bacterial nanocellulose (BNC) stands out among polymers as a promising biomaterial due to its mechanical strength, hydrophilicity, biocompatibility, biodegradability, low toxicity and renewability. The use of scaffolds based on BNC for 3D cell culture has been previously demonstrated. The study exploited excellent properties of the BNC to develop an efficient and low-cost in vitro cell migration assay. The BNC scaffold was introduced into a cell culture 24 h after the SW480 cells were seeded, and cells were allowed to enter the scaffold within the next 24-48 h. The cells were stained with different fluorophores either before or after the introduction of the scaffold in the culture. Untreated cells were observed to enter the BNC scaffold in significant numbers, form clusters and retain a high viability after 48 h. To validate the assay's usability for drug development, the treatments of SW480 cells were performed using aspirin, an agent known to reduce the migratory potential of this cell line in culture. This study demonstrates the application of BNC as a scaffold for cell migration testing as a low-cost alternative to commercial assays based on the Boyden chamber principle. The assay could be further developed for routine use in cancer research and anticancer drug development.",
publisher = "MDPI, Basel",
journal = "Nanomaterials",
title = "Bacterial Nanocellulose as a Scaffold for In Vitro Cell Migration Assay",
number = "9",
volume = "11",
doi = "10.3390/nano11092322"
}

Ugrin, M., Dinić, J., Jeremić, S., Dragičević, S., Banović Đeri, B.,& Nikolić, A.. (2021). Bacterial Nanocellulose as a Scaffold for In Vitro Cell Migration Assay. in Nanomaterials
MDPI, Basel., 11(9).
https://doi.org/10.3390/nano11092322

Ugrin M, Dinić J, Jeremić S, Dragičević S, Banović Đeri B, Nikolić A. Bacterial Nanocellulose as a Scaffold for In Vitro Cell Migration Assay. in Nanomaterials. 2021;11(9).
doi:10.3390/nano11092322 .

Ugrin, Milena, Dinić, Jelena, Jeremić, Sanja, Dragičević, Sandra, Banović Đeri, Bojana, Nikolić, Aleksandra, "Bacterial Nanocellulose as a Scaffold for In Vitro Cell Migration Assay" in Nanomaterials, 11, no. 9 (2021),
https://doi.org/10.3390/nano11092322 . .

TY  - JOUR
AU  - Despotović, Jovana
AU  - Dragičević, Sandra
AU  - Nikolić, Aleksandra
PY  - 2021
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1421
AB  - Metastatic colorectal cancer (mCRC) patients are treated with standard chemotherapeutic drugs in the form of FOLFOX and FOLFIRI regimens. There are no reliable markers that could predict response to chemotherapy for mCRC. TGF-beta signaling which interacts with microRNA (miRNA) network has important roles in tumor progression and chemotherapy resistance, thus the interplay between TGF-beta signaling and miRNAs could be crucial for treatment response. The aim of this study was to analyze the effect of chemotherapy for mCRC on TGF-beta signaling and related miRNAs. Hsa-miR-17-5p, hsa-miR-21-5p and hsa-miR-93-5p were selected out of 316 miRNAs with multiple targets within the TGF-beta signaling by in silico analysis. SW620 cells were treated with chemotherapeutic drugs for mCRC for 1, 3 and 6 days and expression of selected miRNAs, PAI-1, CDH1 and VIM was measured. Expression of TGF-beta signaling-related hsa-miR-17-5p, hsa-miR-21-5p and hsa-miR-93-5p was time-dependently altered in SW620 cells treated with chemotherapeutics for mCRC. The expression of hsa-miR-93-5p remained downregulated after 6 days under combined treatments FOX and FIRI as well as the hsa-miR-17-5p expression under FIRI. Chemotherapy regimens for mCRC increased expression of a major TGF-beta signaling target gene PAI-1, independently of the selected miRNAs expression. These treatments also increased the expression of epithelial-mesenchymal transition (EMT) markers CDH1 and VIM on day 3 resulting in decrease of mesenchymal-like characteristics. However, their expression returned close to basal level on day 6. In conclusion, after initial response to chemotherapeutic drugs SW620 cells start to return close to the basal mesenchymal state while the long-term downregulated expression pattern of hsa-miR-93-5p and hsa-miR-17-5p makes them candidates worth testing as biomarkers for monitoring combined chemotherapeutic treatments therapy response in mCRC patients.
PB  - Humana Press Inc, Totowa
T2  - Cell Biochemistry and Biophysics
T1  - Effects of Chemotherapy for Metastatic Colorectal Cancer on the TGF-beta Signaling and Related miRNAs hsa-miR-17-5p, hsa-miR-21-5p and hsa-miR-93-5p
EP  - 767
IS  - 4
SP  - 757
VL  - 79
DO  - 10.1007/s12013-021-00980-3
ER  - 

@article{
author = "Despotović, Jovana and Dragičević, Sandra and Nikolić, Aleksandra",
year = "2021",
abstract = "Metastatic colorectal cancer (mCRC) patients are treated with standard chemotherapeutic drugs in the form of FOLFOX and FOLFIRI regimens. There are no reliable markers that could predict response to chemotherapy for mCRC. TGF-beta signaling which interacts with microRNA (miRNA) network has important roles in tumor progression and chemotherapy resistance, thus the interplay between TGF-beta signaling and miRNAs could be crucial for treatment response. The aim of this study was to analyze the effect of chemotherapy for mCRC on TGF-beta signaling and related miRNAs. Hsa-miR-17-5p, hsa-miR-21-5p and hsa-miR-93-5p were selected out of 316 miRNAs with multiple targets within the TGF-beta signaling by in silico analysis. SW620 cells were treated with chemotherapeutic drugs for mCRC for 1, 3 and 6 days and expression of selected miRNAs, PAI-1, CDH1 and VIM was measured. Expression of TGF-beta signaling-related hsa-miR-17-5p, hsa-miR-21-5p and hsa-miR-93-5p was time-dependently altered in SW620 cells treated with chemotherapeutics for mCRC. The expression of hsa-miR-93-5p remained downregulated after 6 days under combined treatments FOX and FIRI as well as the hsa-miR-17-5p expression under FIRI. Chemotherapy regimens for mCRC increased expression of a major TGF-beta signaling target gene PAI-1, independently of the selected miRNAs expression. These treatments also increased the expression of epithelial-mesenchymal transition (EMT) markers CDH1 and VIM on day 3 resulting in decrease of mesenchymal-like characteristics. However, their expression returned close to basal level on day 6. In conclusion, after initial response to chemotherapeutic drugs SW620 cells start to return close to the basal mesenchymal state while the long-term downregulated expression pattern of hsa-miR-93-5p and hsa-miR-17-5p makes them candidates worth testing as biomarkers for monitoring combined chemotherapeutic treatments therapy response in mCRC patients.",
publisher = "Humana Press Inc, Totowa",
journal = "Cell Biochemistry and Biophysics",
title = "Effects of Chemotherapy for Metastatic Colorectal Cancer on the TGF-beta Signaling and Related miRNAs hsa-miR-17-5p, hsa-miR-21-5p and hsa-miR-93-5p",
pages = "767-757",
number = "4",
volume = "79",
doi = "10.1007/s12013-021-00980-3"
}

Despotović, J., Dragičević, S.,& Nikolić, A.. (2021). Effects of Chemotherapy for Metastatic Colorectal Cancer on the TGF-beta Signaling and Related miRNAs hsa-miR-17-5p, hsa-miR-21-5p and hsa-miR-93-5p. in Cell Biochemistry and Biophysics
Humana Press Inc, Totowa., 79(4), 757-767.
https://doi.org/10.1007/s12013-021-00980-3

Despotović J, Dragičević S, Nikolić A. Effects of Chemotherapy for Metastatic Colorectal Cancer on the TGF-beta Signaling and Related miRNAs hsa-miR-17-5p, hsa-miR-21-5p and hsa-miR-93-5p. in Cell Biochemistry and Biophysics. 2021;79(4):757-767.
doi:10.1007/s12013-021-00980-3 .

Despotović, Jovana, Dragičević, Sandra, Nikolić, Aleksandra, "Effects of Chemotherapy for Metastatic Colorectal Cancer on the TGF-beta Signaling and Related miRNAs hsa-miR-17-5p, hsa-miR-21-5p and hsa-miR-93-5p" in Cell Biochemistry and Biophysics, 79, no. 4 (2021):757-767,
https://doi.org/10.1007/s12013-021-00980-3 . .

TY  - JOUR
AU  - Stopić, Bojan
AU  - Dragičević, Sandra
AU  - Medić-Brkić, Branislava
AU  - Nikolić, Aleksandra
AU  - Stojanović, Marko
AU  - Budisavljević, Sreten
AU  - Dimković, Nada
PY  - 2021
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1463
AB  - Cardiovascular (CV) morbidity and mortality increase along with the progression of chronic kidney disease (CKD). The potential novel biomarkers of cardiotoxicity have been tested with the aim of the early detection of patients at high CV risk, and among them are markers of inflammation, oxidative stress, acute renal injury, and microRNAs. The study analyzed biomarkers in non-dialysis-dependent (NDD; stage 3a-4 CKD) and dialysis-dependent (DD) CKD patients. The prospective cohort study included 87 patients who were followed for 18 months, during which period newly occurred CV events were recorded. Cox regression analysis confirmed serum albumin, urea, interventricular septum thickness diameter (IVST), the use of calcium antagonist, and erythropoiesis-stimulating agent to be significant predictors of CV outcome. No significant difference was observed in biomarkers of inflammation, oxidative stress, acute kidney injury (IL-18, CRP, ferritin, IMA, SOD, NGAL, and KIM-1), and miR-133a, in regards to the presence/absence of CV event, CV death, and left ventricular hypertrophy. Serum albumin, urea, IVST, and the use of calcium antagonist and erythropoiesis-stimulating agents were confirmed to be factors associated with CV events in CKD patients. Apart from traditional risk factors, new research is needed to define novel and reliable biomarkers of cardiotoxicity in CKD patients.
PB  - MDPI, Basel
T2  - Toxins
T1  - Biomarkers of Uremic Cardiotoxicity
IS  - 9
VL  - 13
DO  - 10.3390/toxins13090639
ER  - 

@article{
author = "Stopić, Bojan and Dragičević, Sandra and Medić-Brkić, Branislava and Nikolić, Aleksandra and Stojanović, Marko and Budisavljević, Sreten and Dimković, Nada",
year = "2021",
abstract = "Cardiovascular (CV) morbidity and mortality increase along with the progression of chronic kidney disease (CKD). The potential novel biomarkers of cardiotoxicity have been tested with the aim of the early detection of patients at high CV risk, and among them are markers of inflammation, oxidative stress, acute renal injury, and microRNAs. The study analyzed biomarkers in non-dialysis-dependent (NDD; stage 3a-4 CKD) and dialysis-dependent (DD) CKD patients. The prospective cohort study included 87 patients who were followed for 18 months, during which period newly occurred CV events were recorded. Cox regression analysis confirmed serum albumin, urea, interventricular septum thickness diameter (IVST), the use of calcium antagonist, and erythropoiesis-stimulating agent to be significant predictors of CV outcome. No significant difference was observed in biomarkers of inflammation, oxidative stress, acute kidney injury (IL-18, CRP, ferritin, IMA, SOD, NGAL, and KIM-1), and miR-133a, in regards to the presence/absence of CV event, CV death, and left ventricular hypertrophy. Serum albumin, urea, IVST, and the use of calcium antagonist and erythropoiesis-stimulating agents were confirmed to be factors associated with CV events in CKD patients. Apart from traditional risk factors, new research is needed to define novel and reliable biomarkers of cardiotoxicity in CKD patients.",
publisher = "MDPI, Basel",
journal = "Toxins",
title = "Biomarkers of Uremic Cardiotoxicity",
number = "9",
volume = "13",
doi = "10.3390/toxins13090639"
}

Stopić, B., Dragičević, S., Medić-Brkić, B., Nikolić, A., Stojanović, M., Budisavljević, S.,& Dimković, N.. (2021). Biomarkers of Uremic Cardiotoxicity. in Toxins
MDPI, Basel., 13(9).
https://doi.org/10.3390/toxins13090639

Stopić B, Dragičević S, Medić-Brkić B, Nikolić A, Stojanović M, Budisavljević S, Dimković N. Biomarkers of Uremic Cardiotoxicity. in Toxins. 2021;13(9).
doi:10.3390/toxins13090639 .

Stopić, Bojan, Dragičević, Sandra, Medić-Brkić, Branislava, Nikolić, Aleksandra, Stojanović, Marko, Budisavljević, Sreten, Dimković, Nada, "Biomarkers of Uremic Cardiotoxicity" in Toxins, 13, no. 9 (2021),
https://doi.org/10.3390/toxins13090639 . .

TY  - CONF
AU  - Despotović, Jovana
AU  - Bogdanović, Aleksandar
AU  - Dragičević, Sandra
AU  - Galun, Danijel
AU  - Krivokapić, Zoran
AU  - Nikolić, Aleksandra
PY  - 2021
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1802
UR  - https://www.eacr2021.org/

https://fightcolorectalcancer.org/blog/recap-rally-on-research-eao-crc/
AB  - Approximately half of colorectal cancer (CRC) patients will develop liver metastases
(CRLM) during the course of the disease. Even with the use of modern adjuvant systemic treatment,
almost two thirds of metastatic colorectal cancer (mCRC) patients will eventually develop recurrent
disease after curative-intent surgery, thus the new prognostic biomarkers are necessary. The expression
signatures of microRNAs (miRNAs), a class of non-coding RNAs, have been associated with the
diagnosis, prognosis, and therapeutic response in CRC. The expression pattern and prognostic potential of
miR-93-5p has been studied previously in CRC but not in mCRC. The aim of this study was to examine
the expression pattern and prognostic potential of tumoral and circulating miR-93-5p in patients with
CRLM.
PB  - EACR 2021 Virtual Congress: Innovative Cancer Science
C3  - European Association for Cancer Research
T1  - Prognostic potential of circulating miR-93-5p in patients with colorectal liver metastases
UR  - https://hdl.handle.net/21.15107/rcub_imagine_1802
ER  - 

@conference{
author = "Despotović, Jovana and Bogdanović, Aleksandar and Dragičević, Sandra and Galun, Danijel and Krivokapić, Zoran and Nikolić, Aleksandra",
year = "2021",
abstract = "Approximately half of colorectal cancer (CRC) patients will develop liver metastases
(CRLM) during the course of the disease. Even with the use of modern adjuvant systemic treatment,
almost two thirds of metastatic colorectal cancer (mCRC) patients will eventually develop recurrent
disease after curative-intent surgery, thus the new prognostic biomarkers are necessary. The expression
signatures of microRNAs (miRNAs), a class of non-coding RNAs, have been associated with the
diagnosis, prognosis, and therapeutic response in CRC. The expression pattern and prognostic potential of
miR-93-5p has been studied previously in CRC but not in mCRC. The aim of this study was to examine
the expression pattern and prognostic potential of tumoral and circulating miR-93-5p in patients with
CRLM.",
publisher = "EACR 2021 Virtual Congress: Innovative Cancer Science",
journal = "European Association for Cancer Research",
title = "Prognostic potential of circulating miR-93-5p in patients with colorectal liver metastases",
url = "https://hdl.handle.net/21.15107/rcub_imagine_1802"
}

Despotović, J., Bogdanović, A., Dragičević, S., Galun, D., Krivokapić, Z.,& Nikolić, A.. (2021). Prognostic potential of circulating miR-93-5p in patients with colorectal liver metastases. in European Association for Cancer Research
EACR 2021 Virtual Congress: Innovative Cancer Science..
https://hdl.handle.net/21.15107/rcub_imagine_1802

Despotović J, Bogdanović A, Dragičević S, Galun D, Krivokapić Z, Nikolić A. Prognostic potential of circulating miR-93-5p in patients with colorectal liver metastases. in European Association for Cancer Research. 2021;.
https://hdl.handle.net/21.15107/rcub_imagine_1802 .

Despotović, Jovana, Bogdanović, Aleksandar, Dragičević, Sandra, Galun, Danijel, Krivokapić, Zoran, Nikolić, Aleksandra, "Prognostic potential of circulating miR-93-5p in patients with colorectal liver metastases" in European Association for Cancer Research (2021),
https://hdl.handle.net/21.15107/rcub_imagine_1802 .

TY  - JOUR
AU  - Rosić, Jovana
AU  - Dragičević, Sandra
AU  - Miladinov, Marko
AU  - Despotović, Jovana
AU  - Bogdanović, Aleksandar
AU  - Krivokapić, Zoran
AU  - Nikolić, Aleksandra
PY  - 2021
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1469
AB  - Inhibitory SMAD7 and common mediator SMAD4 play crucial roles in SMAD-dependent TGF-I3 signaling that is often disrupted in colorectal cancer (CRC). This study aimed to profile the expression of SMAD7 and SMAD4 in primary and metastatic CRC and to evaluate their significance in disease progression and therapy response. The expression of SMAD7 and SMAD4 genes was analyzed by quantitative real-time PCR in tissues from 35 primary and metastatic CRC patients and in vitro in 7 human cell lines originating from colon tissue. Expression levels of SMAD7 and SMAD4, as well as their ratio, were determined and their association with tumor characteristics and response to therapy were evaluated. SMAD4 level was significantly lower in tumors compared to non-tumor tissues in both primary (p = 0.001) and metastatic (p = 0.001) CRC patients, while tumor expression of SMAD7 was significantly lower from non-tumor tissue only in metastatic patients (p = 0.017). SMAD7/SMAD4 ratio was elevated in CRC primary tumor tissues and cell lines compared to corresponding non-tumor tissues and cell line, respectively (p = 0.003). SMAD7 expression was significantly elevated in primary tumor tissues obtained from responders to neoadjuvant chemoradiotherapy (nCRT) compared to non-responders (p = 0.014). Alterations of expression and ratio of SMAD7 and SMAD4 in CRC cell lines, primary rectal cancer, and liver metastasis emphasize the importance of these genes in different stages of disease progression. Differential expression of SMAD7 in responders versus non-responders to nCRT should be further investigated for its potential predictive value.
PB  - Academic Press Inc Elsevier Science, San Diego
T2  - Experimental and Molecular Pathology
T1  - SMAD7 and SMAD4 expression in colorectal cancer progression and therapy response
VL  - 123
DO  - 10.1016/j.yexmp.2021.104714
ER  - 

@article{
author = "Rosić, Jovana and Dragičević, Sandra and Miladinov, Marko and Despotović, Jovana and Bogdanović, Aleksandar and Krivokapić, Zoran and Nikolić, Aleksandra",
year = "2021",
abstract = "Inhibitory SMAD7 and common mediator SMAD4 play crucial roles in SMAD-dependent TGF-I3 signaling that is often disrupted in colorectal cancer (CRC). This study aimed to profile the expression of SMAD7 and SMAD4 in primary and metastatic CRC and to evaluate their significance in disease progression and therapy response. The expression of SMAD7 and SMAD4 genes was analyzed by quantitative real-time PCR in tissues from 35 primary and metastatic CRC patients and in vitro in 7 human cell lines originating from colon tissue. Expression levels of SMAD7 and SMAD4, as well as their ratio, were determined and their association with tumor characteristics and response to therapy were evaluated. SMAD4 level was significantly lower in tumors compared to non-tumor tissues in both primary (p = 0.001) and metastatic (p = 0.001) CRC patients, while tumor expression of SMAD7 was significantly lower from non-tumor tissue only in metastatic patients (p = 0.017). SMAD7/SMAD4 ratio was elevated in CRC primary tumor tissues and cell lines compared to corresponding non-tumor tissues and cell line, respectively (p = 0.003). SMAD7 expression was significantly elevated in primary tumor tissues obtained from responders to neoadjuvant chemoradiotherapy (nCRT) compared to non-responders (p = 0.014). Alterations of expression and ratio of SMAD7 and SMAD4 in CRC cell lines, primary rectal cancer, and liver metastasis emphasize the importance of these genes in different stages of disease progression. Differential expression of SMAD7 in responders versus non-responders to nCRT should be further investigated for its potential predictive value.",
publisher = "Academic Press Inc Elsevier Science, San Diego",
journal = "Experimental and Molecular Pathology",
title = "SMAD7 and SMAD4 expression in colorectal cancer progression and therapy response",
volume = "123",
doi = "10.1016/j.yexmp.2021.104714"
}

Rosić, J., Dragičević, S., Miladinov, M., Despotović, J., Bogdanović, A., Krivokapić, Z.,& Nikolić, A.. (2021). SMAD7 and SMAD4 expression in colorectal cancer progression and therapy response. in Experimental and Molecular Pathology
Academic Press Inc Elsevier Science, San Diego., 123.
https://doi.org/10.1016/j.yexmp.2021.104714

Rosić J, Dragičević S, Miladinov M, Despotović J, Bogdanović A, Krivokapić Z, Nikolić A. SMAD7 and SMAD4 expression in colorectal cancer progression and therapy response. in Experimental and Molecular Pathology. 2021;123.
doi:10.1016/j.yexmp.2021.104714 .

Rosić, Jovana, Dragičević, Sandra, Miladinov, Marko, Despotović, Jovana, Bogdanović, Aleksandar, Krivokapić, Zoran, Nikolić, Aleksandra, "SMAD7 and SMAD4 expression in colorectal cancer progression and therapy response" in Experimental and Molecular Pathology, 123 (2021),
https://doi.org/10.1016/j.yexmp.2021.104714 . .

TY  - CONF
AU  - Rosić, J.
AU  - Dragičević, Sandra
AU  - Miladinov, M.
AU  - Despotović, Jovana
AU  - Bogdanović, A.
AU  - Krivokapić, Z.
AU  - Nikolić, Aleksandra
PY  - 2021
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1452
PB  - Wiley, Hoboken
C3  - FEBS Open Bio
T1  - SMAD7 and SMAD4 expression and ratio in primary and metastatic colorectal cancer
EP  - 433
SP  - 433
VL  - 11
UR  - https://hdl.handle.net/21.15107/rcub_imagine_1452
ER  - 

@conference{
author = "Rosić, J. and Dragičević, Sandra and Miladinov, M. and Despotović, Jovana and Bogdanović, A. and Krivokapić, Z. and Nikolić, Aleksandra",
year = "2021",
publisher = "Wiley, Hoboken",
journal = "FEBS Open Bio",
title = "SMAD7 and SMAD4 expression and ratio in primary and metastatic colorectal cancer",
pages = "433-433",
volume = "11",
url = "https://hdl.handle.net/21.15107/rcub_imagine_1452"
}

Rosić, J., Dragičević, S., Miladinov, M., Despotović, J., Bogdanović, A., Krivokapić, Z.,& Nikolić, A.. (2021). SMAD7 and SMAD4 expression and ratio in primary and metastatic colorectal cancer. in FEBS Open Bio
Wiley, Hoboken., 11, 433-433.
https://hdl.handle.net/21.15107/rcub_imagine_1452

Rosić J, Dragičević S, Miladinov M, Despotović J, Bogdanović A, Krivokapić Z, Nikolić A. SMAD7 and SMAD4 expression and ratio in primary and metastatic colorectal cancer. in FEBS Open Bio. 2021;11:433-433.
https://hdl.handle.net/21.15107/rcub_imagine_1452 .

Rosić, J., Dragičević, Sandra, Miladinov, M., Despotović, Jovana, Bogdanović, A., Krivokapić, Z., Nikolić, Aleksandra, "SMAD7 and SMAD4 expression and ratio in primary and metastatic colorectal cancer" in FEBS Open Bio, 11 (2021):433-433,
https://hdl.handle.net/21.15107/rcub_imagine_1452 .

TY  - JOUR
AU  - Dragičević, Sandra
AU  - Kovacević, Draginja
AU  - Divac Rankov, Aleksandra
AU  - Nikolić, Aleksandra
AU  - Radojković, Dragica
AU  - Radović, Svetlana
PY  - 2019
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1233
AB  - Tussilago farfara (coltsfoot) and Verbascum thapsus (mullein) have been used as folk remedies for treating respiratory disorders. The aim of this study was to test the toxicity of the water extracts of T. farfara and V. thapsus in vivo in zebrafish and in vitro in BEAS 2B epithelial bronchial cells. To the best of our knowledge, this is the first study to investigate the antioxidative properties of T. farfara and V. thapsus extracts in cell culture. Our results show that the T. farfara leaf extract does not produce toxic effects on zebrafish embryos or BEAS 2B cells, and that it has a protective effect in BEAS 2B after induction of oxidative stress. The water extract from V. thapsus displayed pronounced toxic effects on zebrafish embryos and BEAS 2B cells and did not exhibit a significant antioxidative effect on BEAS 2B cells exposed to oxidative stress. Our results suggest that the use of T. farfara water leaf extract is potentially safe and effective in treating respiratory disorders, whereas the use of V. thapsus needs further investigation.
PB  - Srpsko biološko društvo, Beograd, i dr.
T2  - Archives of Biological Sciences
T1  - Evaluation of toxicity and antioxidative effects of Tussilago farfara and Verbascum thapsus water extracts in zebrafish and in bronchial epithelial cells
EP  - 416
IS  - 3
SP  - 409
VL  - 71
DO  - 10.2298/ABS181213022D
ER  - 

@article{
author = "Dragičević, Sandra and Kovacević, Draginja and Divac Rankov, Aleksandra and Nikolić, Aleksandra and Radojković, Dragica and Radović, Svetlana",
year = "2019",
abstract = "Tussilago farfara (coltsfoot) and Verbascum thapsus (mullein) have been used as folk remedies for treating respiratory disorders. The aim of this study was to test the toxicity of the water extracts of T. farfara and V. thapsus in vivo in zebrafish and in vitro in BEAS 2B epithelial bronchial cells. To the best of our knowledge, this is the first study to investigate the antioxidative properties of T. farfara and V. thapsus extracts in cell culture. Our results show that the T. farfara leaf extract does not produce toxic effects on zebrafish embryos or BEAS 2B cells, and that it has a protective effect in BEAS 2B after induction of oxidative stress. The water extract from V. thapsus displayed pronounced toxic effects on zebrafish embryos and BEAS 2B cells and did not exhibit a significant antioxidative effect on BEAS 2B cells exposed to oxidative stress. Our results suggest that the use of T. farfara water leaf extract is potentially safe and effective in treating respiratory disorders, whereas the use of V. thapsus needs further investigation.",
publisher = "Srpsko biološko društvo, Beograd, i dr.",
journal = "Archives of Biological Sciences",
title = "Evaluation of toxicity and antioxidative effects of Tussilago farfara and Verbascum thapsus water extracts in zebrafish and in bronchial epithelial cells",
pages = "416-409",
number = "3",
volume = "71",
doi = "10.2298/ABS181213022D"
}

Dragičević, S., Kovacević, D., Divac Rankov, A., Nikolić, A., Radojković, D.,& Radović, S.. (2019). Evaluation of toxicity and antioxidative effects of Tussilago farfara and Verbascum thapsus water extracts in zebrafish and in bronchial epithelial cells. in Archives of Biological Sciences
Srpsko biološko društvo, Beograd, i dr.., 71(3), 409-416.
https://doi.org/10.2298/ABS181213022D

Dragičević S, Kovacević D, Divac Rankov A, Nikolić A, Radojković D, Radović S. Evaluation of toxicity and antioxidative effects of Tussilago farfara and Verbascum thapsus water extracts in zebrafish and in bronchial epithelial cells. in Archives of Biological Sciences. 2019;71(3):409-416.
doi:10.2298/ABS181213022D .

Dragičević, Sandra, Kovacević, Draginja, Divac Rankov, Aleksandra, Nikolić, Aleksandra, Radojković, Dragica, Radović, Svetlana, "Evaluation of toxicity and antioxidative effects of Tussilago farfara and Verbascum thapsus water extracts in zebrafish and in bronchial epithelial cells" in Archives of Biological Sciences, 71, no. 3 (2019):409-416,
https://doi.org/10.2298/ABS181213022D . .